var title_f31_49_32528="Hydrocortisone: Drug information";
var content_f31_49_32528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocortisone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/48/8969?source=see_link\">",
"       Hydrocortisone (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/54/21352?source=see_link\">",
"       Hydrocortisone (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8535 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32528=[""].join("\n");
var outline_f31_49_32528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/48/8969?source=related_link\">",
"      Hydrocortisone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/54/21352?source=related_link\">",
"      Hydrocortisone (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_49_32529="Mini-case session #2: Water and sodium balance: Part B";
var content_f31_49_32529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mini-case session #2: Water and sodium balance: Part B",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32529/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32529/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32529/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32529/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32529/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/49/32529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 28, 1995.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 58 year-old man who weighs 70 kg has the syndrome of inappropriate ADH secretion and chronic hyponatremia due to an oat cell carcinoma of the lung. This disorder is characterized by abnormal water handling (due to the persistent presence of ADH), but normal sodium handling since the sodium regulatory hormones are not affected. On admission:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Plasma sodium &nbsp;= &nbsp;120",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urine osmolality &nbsp;= &nbsp;600",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urine sodium &nbsp;= &nbsp;80",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"   </p>",
"   <p>",
"    The plasma sodium concentration remains stable at 120",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;A. &nbsp;What is the major determinant of urinary sodium excretion in this setting? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;B. &nbsp;What is the normal urine sodium concentration?",
"   </p>",
"   <p>",
"    &nbsp;C. &nbsp;If the patient is given two liters of isotonic saline (containing 150 meq of Na and 150 meq of Cl per liter) per day:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;1. &nbsp;How much of the administered sodium will be excreted in the steady-state? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;2. &nbsp;How much of the administered water will be excreted (assuming that the urine osmolality remains constant)?",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;3. &nbsp;What will be the net effect on the plasma sodium concentration?",
"   </p>",
"   <p>",
"    &nbsp;D. &nbsp;Suppose this patient continued to ingest water that could not be excreted as free water because ADH levels remain elevated. What would protect against progressive volume expansion? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Determinants of urine output'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;E. &nbsp;How can a patient with the SIADH have a normal plasma sodium concentration of 140",
"    <span class=\"nowrap\">",
"     meq/L?",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;F. &nbsp;In normal subjects, what is the major protection against the development of hyponatremia and hypernatremia?",
"   </p>",
"   <p>",
"    &nbsp;G. &nbsp;Why do you think this patient with chronic hyponatremia is asymptomatic? What implications does this have for the rate of correction of the plasma sodium concentration? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 68 year-old man had a motor vehicle accident with head trauma 17 years ago. Since that time, he has had persistent polyuria and polydipsia, requiring voiding every 1 to 2 h during the night. A CT scan reveals marked calcification in the region of the hypothalamus.",
"   </p>",
"   <p>",
"    A diagnosis of central diabetes insipidus is made. On 2 separate occasions in the past, dDAVP (an analog of ADH that has antidiuretic but not vasopressor activity) is tried in low doses but leads to a reduction in the plasma sodium concentration to about 125",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient is currently on no medications and has the following laboratory findings:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Plasma sodium &nbsp;= &nbsp;138",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urine osmolality &nbsp;= &nbsp;201",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;A. &nbsp;What are some basic mechanisms by which there might be an increase in urinary water output? Consider the mechanisms by which water is reabsorbed in each of the nephron segments.",
"   </p>",
"   <p>",
"    &nbsp;B. &nbsp;How would you evaluate the patient's polyuria? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7245 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-218.7.204.202-34378B5ED4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32529=[""].join("\n");
var outline_f31_49_32529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_49_32530="Bone marrow aplastic anemia";
var content_f31_49_32530=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone marrow of a child with aplastic anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Min Xu, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32530=[""].join("\n");
var outline_f31_49_32530=null;
var title_f31_49_32531="Lutropin alfa: Drug information";
var content_f31_49_32531=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lutropin alfa: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/46/1764?source=see_link\">",
"    see \"Lutropin alfa: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Luveris&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gonadotropin;",
"     </li>",
"     <li>",
"      Ovulation Stimulator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Infertility:",
"     </b>",
"     Females: SubQ: 75 units daily until adequate follicular development is noted; maximum duration of treatment: 14 days, unless signs of imminent follicular development are present; to be used concomitantly with follitropin alfa. Once adequate follicular development is evident, administer hCG to induce final follicular maturation in preparation for oocyte retrieval. Withhold hCG if the ovaries are abnormally enlarged.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13812287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13812288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Luveris&reg;: 75 units [DSC] [contains sucrose 48 mg; derived from or manufactured using Chinese hamster ovary cells; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F190550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Administer on the stomach, a few inches above or below the navel. Do not shake solution; allow any bubbles to settle prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulation of follicular development in infertile hypogonadotropic hypogonadal (HH) women with profound luteinizing hormone (LH) deficiency (&lt;1.2 units/L); to be used in combination with follitropin alfa",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F190575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (10%), fatigue (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Ovarian hyperstimulation (6%), breast pain (5% to 6 %), dysmenorrhea (2% to 3%), ovarian disorder (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (7%), constipation (2% to 3%), diarrhea (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adverse events reported with gonadotropin or menotropin therapy: Adnexal torsion, arterial thromboembolism, congenital abnormalities, ectopic pregnancy, hemoperitoneum, ovarian enlargement (mild-to-moderate), ovarian neoplasms (infrequent), postpartum fever, premature labor, pulmonary complications, spontaneous abortion, vascular complications",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lutropin alfa or any component of the formulation; primary ovarian failure; uncontrolled thyroid or adrenal dysfunction; uncontrolled organic intracranial lesion (eg, pituitary tumor); abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement of undetermined origin; sex hormone-dependent tumors of the reproductive tract and accessory organs; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F190539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian enlargement: May be accompanied by abdominal distention or abdominal pain and generally regresses without treatment within 2-3 weeks. If ovaries are abnormally enlarged on the last day of treatment, withhold hCG to reduce the risk of ovarian hyperstimulation syndrome (OHSS).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian hyperstimulation syndrome (OHSS): OHSS is characterized by severe ovarian enlargement, abdominal pain/distention, nausea, vomiting, diarrhea, dyspnea, and oliguria, and may be accompanied by ascites, pleural effusion, hypovolemia, electrolyte imbalance, hemoperitoneum, and thromboembolic events. If hyperstimulation occurs, stop treatment and hospitalize patient. This syndrome develops rapidly within 24 hours to several days and generally occurs after treatment has ended and reaches its maximum on days 7-10 following treatment. Hemoconcentration associated with fluid loss into the abdominal cavity has occurred and should be assessed by fluid intake and output, weight, hematocrit, serum and urinary electrolytes, urine specific gravity, BUN and creatinine, and abdominal girth. Determinations should be performed daily or more often if the need arises. Treatment is primarily symptomatic and consists of bedrest, fluid and electrolyte replacement, and analgesics. The ascitic, pleural, and pericardial fluids should not be removed unless needed to relieve symptoms of cardiopulmonary distress.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: In association with and separate from ovarian hyperstimulation syndrome (OHSS), thromboembolic events have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: To minimize risks, use only at the lowest effective dose. Monitor ovarian response with serum estradiol and vaginal ultrasound on a regular basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician: These medications should only be used by physicians who are thoroughly familiar with infertility problems and their management.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple births: May result from the use of these medications; advise patients of the potential risk of multiple births before starting the treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F190544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F190554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Ectopic pregnancy, congenital abnormalities, and multiple births have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F190568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F190546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prior to therapy: Baseline LH &lt;1.2 units/L, FSH &lt;5 units/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Monitor sufficient follicular maturation. This may be directly estimated by sonographic visualization of the ovaries and endometrial lining or measuring serum estradiol levels. The combination of both ultrasonography and measurement of estradiol levels is useful for monitoring for the growth and development of follicles and timing hCG administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The clinical evaluation of estrogenic activity (changes in vaginal cytology and changes in appearance and volume of cervical mucus) provides an indirect estimate of the estrogenic effect upon the target organs and, therefore, it should only be used adjunctively with more direct estimates of follicular development (ultrasonography and serum estradiol determinations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The clinical confirmation of ovulation is obtained by direct and indirect indices of progesterone production. The indices most generally used are: rise in basal body temperature, increase in serum progesterone, and menstruation following the shift in basal body temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Monitor for signs and symptoms of OHSS for at least 2 weeks following hCG administration.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F190555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Luver-I.S. (MX);",
"     </li>",
"     <li>",
"      Luveris (AR, AT, AU, BE, BR, CH, CL, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IN, IT, KP, MY, NL, NO, NZ, PH, PL, PT, RU, SE, SG, TR, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F190538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lutropin alfa is a recombinant luteinizing hormone prepared using Chinese hamster cell ovaries. Administration leads to increased follicular estradiol secretion needed for follicle stimulating hormone induced follicular development.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F190552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 10 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 56% &plusmn; 23%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: ~18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 4-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;5% unchanged)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10239 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32531=[""].join("\n");
var outline_f31_49_32531=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190565\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190577\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190566\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13812287\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13812288\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190548\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190536\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190550\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190549\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190575\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190553\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190539\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299623\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221384\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190544\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190554\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190568\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190546\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190555\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190538\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190552\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10239\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10239|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/46/1764?source=related_link\">",
"      Lutropin alfa: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_49_32532="Transabdominal cervical cerclage";
var content_f31_49_32532=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transabdominal cervical cerclage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32532/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32532/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32532/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32532/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32532/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32532/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/49/32532/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal placement of a cerclage at the cervicoisthmic junction appears to be a safe and effective procedure for reducing the incidence of spontaneous pregnancy loss in selected patients with cervical insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Potential advantages of transabdominal over transvaginal cerclage are more proximal placement of the stitch (at the level of the internal os), decreased risk of suture migration, absence of a foreign body in the vagina that could promote infection, and the ability to leave the suture in place for future pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/4\">",
"     4",
"    </a>",
"    ]. A disadvantage of this approach is the potential need for two laparotomies during pregnancy (one to place the cerclage and potentially another to remove it).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies comparing the outcome of transabdominal and transvaginal cerclage in similar populations of patients. Transabdominal cerclage is a more morbid procedure than transvaginal cerclage. It usually requires a laparotomy for placement and delivery by cesarean. For these reasons, most experts recommend reserving the transabdominal approach for women with cervical insufficiency who have either failed two or more previous transvaginal cerclages or in whom a transvaginal cerclage is technically impossible to perform due to extreme shortening, scarring, or laceration of the cervix.",
"   </p>",
"   <p>",
"    Contraindications to transabdominal cerclage are similar to those for transvaginal cervical cerclage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=see_link&amp;anchor=H4#H4\">",
"     \"Transvaginal cervical cerclage\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TIMING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal cerclage placement is usually performed either prior to conception [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/7\">",
"     7",
"    </a>",
"    ] or during early pregnancy (at 11 to 14 weeks). Placement of the cerclage later in pregnancy is undesirable since the large size of the uterus makes the procedure difficult and thus may be associated with a higher risk of complications.",
"   </p>",
"   <p>",
"    No studies have compared the outcome of patients who underwent surgery prior to conception versus those whose placement was in early pregnancy. Although the preconceptional approach is associated with less blood loss and avoids the risk of pregnancy-associated complications (eg, rupture of the fetal membranes), there is a theoretic risk of causing subfertility with preconceptional placement [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/1\">",
"     1",
"    </a>",
"    ]. Our preference is to perform the procedure in early pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Open transabdominal approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure is usually performed with the patient in the supine position, but may be done with the woman in a modified lithotomy position if intraoperative transvaginal manipulation of the uterus or transvaginal ultrasound examination of the cervix is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The abdominal cavity is entered through a transverse or vertical incision and the peritoneal bladder reflection is taken down by sharp and blunt dissection to expose the cervicoisthmic junction, the uterine artery, and the parametrial vessels. The uterine vessels can be palpated between the thumb and forefinger and should be drawn laterally away from the uterus, thereby exposing an avascular space immediately adjacent to the cervicoisthmic junction. It may help to have an assistant elevate and cradle the uterus out of the pelvis in order to provide optimum exposure of the vessels and isthmus. Gentle handling of the uterus is particularly important during pregnancy to avoid kinking the uterine blood supply and disrupting the placenta and to maintain uterine quiescence.",
"   </p>",
"   <p>",
"    The avascular space at the level of the cervicouterine junction between the lateral wall of the uterus and the ascending and descending branches of the uterine arteries is identified. A 15 cm long 5-mm Mersilene band is passed through this space from anterior to posterior. This can be achieved using a Mersilene band preloaded onto a needle, or by creating a tunnel through this avascular space and the posterior leaf of the broad ligament using a long right-angled forcep or Moynihan clamp. Care should be taken as the nearby veins are prone to injury. The identical procedure is repeated on the opposite side, except the needle is passed from posterior to anterior.",
"   </p>",
"   <p>",
"    The Mersilene band should be wrapped around the posterior uterine isthmus at the level of the uterosacral ligament insertions, made to lie flat against the uterus, tied to slightly compress the intervening tissue, and secured with a triple square knot (",
"    <a class=\"graphic graphic_figure graphicRef65514 \" href=\"UTD.htm?26/44/27328\">",
"     figure 1",
"    </a>",
"    ). The ends can be sutured to the band with fine nonabsorbable sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/8\">",
"     8",
"    </a>",
"    ]. Ultrasound is occasionally used to monitor the fetal heart rate to ascertain that blood flow through the uterine artery has not been compromised by the procedure, and to ensure that the membranes are above the level of the cerclage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Laparoscopic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic placement and removal of a transabdominal cerclage has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/7,9-13\">",
"     7,9-13",
"    </a>",
"    ]. Although this approach has yet to be studied in a systematic fashion, it remains a promising option for the management of cervical insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Transvaginal approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transvaginal approach to the cervicoisthmic area has also been described. It involves placement of a 'high' Shirodkar cerclage at the level of the cervicoisthmic junction after surgical reflection of the bladder anteriorly and the rectum posteriorly. It appears to be less morbid than the transabdominal approach and to have similar efficacy if actually placed in the cervicoisthmic area, but experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative follow-up is similar to that with transvaginal cerclage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=see_link&amp;anchor=H10#H10\">",
"     \"Transvaginal cervical cerclage\", section on 'Postoperative care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major intraoperative complication is bleeding from inadvertent damage to adjacent vessels. The risk of this can be minimized if the cerclage is placed prior to conception, when the pelvic vessels are smaller [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/1\">",
"     1",
"    </a>",
"    ]. Other adverse events described in case reports and case series include fetal death and intrauterine growth restriction (from inadvertent ligation of the uterine arteries), suture migration, infection, premature labor, premature rupture of membranes, uterine rupture, rectovaginal fistula, and maternal discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In one large series of 300 procedures performed over a 24-year time span, fetal loss (prior to 20 weeks) occurred in 4.1 percent of pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/19\">",
"     19",
"    </a>",
"    ]. Surgical complications occurred in 11 cases (3.7 percent), median estimated blood loss was 100 mL, lower uterine dehiscence occurred in four patients, and uterine rupture occurred in one patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest elective cesarean delivery at 37 to 39 weeks of gestation after confirmation of fetal lung maturity if the gestation is less than 39 weeks. At cesarean, the infant is delivered through a hysterotomy incision made above the cerclage. The Mersilene band can then be removed, or left in place if future pregnancies are planned. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=see_link\">",
"     \"Assessment of fetal lung maturity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF FETAL DEMISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the event of a fetal loss in the first trimester, cervical dilation and evacuation of the uterus can be safely and effectively performed without removal of the transabdominal cerclage. It is not clear whether these procedures can be successfully accomplished for a second trimester pregnancy loss. It may be technically feasible to remove the cerclage through a transvaginal colpotomy, thereby permitting vaginal delivery. However, in practice, this technique is far more difficult than reported and is not generally recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any surgical procedure, the technical skill and experience of the operator are important factors for a successful outcome. Transabdominal cerclage has been advocated for women who failed transvaginal procedures in previous pregnancies. This issue was addressed in a systematic review that evaluated pregnancy outcome after these procedures in women whose prior pregnancy ended in midtrimester loss or preterm delivery before 34 weeks despite placement of a transvaginal cerclage [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/20\">",
"     20",
"    </a>",
"    ]. Transabdominal cerclage in this setting was associated with a lower likelihood of perinatal death or delivery before 24 weeks of gestation (6 versus 12.5 percent with repeat transvaginal cerclage), but a higher rate of serious operative complications, such as need for transfusion or organ injury (3 versus 0 percent). Subsequent studies have reported similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/18,21\">",
"     18,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a literature review identified 276 women who underwent transabdominal cerclage during 306 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/18\">",
"     18",
"    </a>",
"    ]. Fetal survival in pregnancies before and after transabdominal cerclage was 2.5 to 55 percent and 60 to 100 percent, respectively. These data need to be interpreted with caution since management of these women and their clinical status may have been different during the \"before\" and \"after\" pregnancies.",
"   </p>",
"   <p>",
"    In a retrospective cohort study of 141 triplet pregnancies that underwent prophylactic transabdominal or transvaginal cerclage or no cerclage, prophylactic transabdominal cerclage was associated with a reduced incidence of extreme prematurity (&lt;28 weeks) and improved",
"    <span class=\"nowrap\">",
"     neonatal/postnatal",
"    </span>",
"    survival [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32532/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A transabdominal cerclage is placed at the cervicoisthmic junction. This approach has several potential advantages over the transvaginal approach: it is easier to locate the stitch at the level of the internal os, there is decreased risk of suture migration, there is no foreign body in the vagina that could promote infection, and the suture can be left in situ for future pregnancies. However, placement and removal generally require laparotomy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest reserving the transabdominal approach to women with cervical insufficiency who have either failed previous transvaginal cerclages or in whom a transvaginal cerclage is technically impossible to perform due to extreme shortening, scarring, or laceration of the cervix (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transabdominal cerclage placement can be performed prior to conception or during early pregnancy (11 to 14 weeks of gestation). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cerclage consists of a Mersilene band wrapped around the cervicouterine isthmus at the level of the uterosacral ligament insertions and tied to slightly compress the intervening tissue. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest delivery by cesarean (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The infant is delivered through a hysterotomy incision made above the stitch; the stitch can then be removed, or left in place if future pregnancies are planned. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Delivery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/1\">",
"      Norwitz, ER, Lee, DM, Goldstein, DP. Transabdominal cervicoisthmic cerclage: Placing the stitch before conception. J Gynecol Tech 1997; 3:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/2\">",
"      Novy MJ. Transabdominal cervicoisthmic cerclage: a reappraisal 25 years after its introduction. Am J Obstet Gynecol 1991; 164:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/3\">",
"      Novy MJ. Transabdominal cervicoisthmic cerclage for the management of repetitive abortion and premature delivery. Am J Obstet Gynecol 1982; 143:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/4\">",
"      Herron MA, Parer JT. Transabdominal cerclage for fetal wastage due to cervical incompetence. Obstet Gynecol 1988; 71:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/5\">",
"      Fick AL, Caughey AB, Parer JT. Transabdominal cerclage: can we predict who fails? J Matern Fetal Neonatal Med 2007; 20:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/6\">",
"      Umstad MP, Quinn MA, Ades A. Transabdominal cervical cerclage. Aust N Z J Obstet Gynaecol 2010; 50:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/7\">",
"      Burger NB, Einarsson JI, Br&ouml;lmann HA, et al. Preconceptional laparoscopic abdominal cerclage: a multicenter cohort study. Am J Obstet Gynecol 2012; 207:273.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/8\">",
"      Norwitz, ER, Goldstein, DP. Transabdominal cervicoisthmic cerclage: Learning to tie the knot. J Gynecol Tech 1996; 2:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/9\">",
"      Gallot D, Savary D, Laurichesse H, et al. Experience with three cases of laparoscopic transabdominal cervico-isthmic cerclage and two subsequent pregnancies. BJOG 2003; 110:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/10\">",
"      Cho CH, Kim TH, Kwon SH, et al. Laparoscopic transabdominal cervicoisthmic cerclage during pregnancy. J Am Assoc Gynecol Laparosc 2003; 10:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/11\">",
"      Carter JF, Soper DE, Goetzl LM, Van Dorsten JP. Abdominal cerclage for the treatment of recurrent cervical insufficiency: laparoscopy or laparotomy? Am J Obstet Gynecol 2009; 201:111.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/12\">",
"      Whittle WL, Singh SS, Allen L, et al. Laparoscopic cervico-isthmic cerclage: surgical technique and obstetric outcomes. Am J Obstet Gynecol 2009; 201:364.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/13\">",
"      Riiskjaer M, Petersen OB, Uldbjerg N, et al. Feasibility and clinical effects of laparoscopic abdominal cerclage: an observational study. Acta Obstet Gynecol Scand 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/14\">",
"      Katz M, Abrahams C. Transvaginal placement of cervicoisthmic cerclage: report on pregnancy outcome. Am J Obstet Gynecol 2005; 192:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/15\">",
"      Golfier F, Bessai K, Paparel P, et al. Transvaginal cervicoisthmic cerclage as an alternative to the transabdominal technique. Eur J Obstet Gynecol Reprod Biol 2001; 100:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/16\">",
"      Witt MU, Joy SD, Clark J, et al. Cervicoisthmic cerclage: transabdominal vs transvaginal approach. Am J Obstet Gynecol 2009; 201:105.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/17\">",
"      Deffieux X, De Tayrac R, Louafi N, et al. Novel application of polypropylene sling: transvaginal cervicoisthmic cerclage in women with high risk of preterm delivery. J Minim Invasive Gynecol 2006; 13:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/18\">",
"      Debbs RH, DeLa Vega GA, Pearson S, et al. Transabdominal cerclage after comprehensive evaluation of women with previous unsuccessful transvaginal cerclage. Am J Obstet Gynecol 2007; 197:317.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/19\">",
"      Foster TL, Moore ES, Sumners JE. Operative complications and fetal morbidity encountered in 300 prophylactic transabdominal cervical cerclage procedures by one obstetric surgeon. J Obstet Gynaecol 2011; 31:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/20\">",
"      Zaveri V, Aghajafari F, Amankwah K, Hannah M. Abdominal versus vaginal cerclage after a failed transvaginal cerclage: a systematic review. Am J Obstet Gynecol 2002; 187:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/21\">",
"      Lotgering FK, Gaugler-Senden IP, Lotgering SF, Wallenburg HC. Outcome after transabdominal cervicoisthmic cerclage. Obstet Gynecol 2006; 107:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32532/abstract/22\">",
"      Sumners JE, Moore ES, Ramsey CJ, Eggleston MK. Transabdominal cervical cerclage in triplet pregnancies and risk of extreme prematurity and neonatal loss. J Obstet Gynaecol 2011; 31:111.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6739 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32532=[""].join("\n");
var outline_f31_49_32532=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIMING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Open transabdominal approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Laparoscopic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Transvaginal approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT OF FETAL DEMISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6739\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6739|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/44/27328\" title=\"figure 1\">",
"      Transabdominal cerclage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=related_link\">",
"      Assessment of fetal lung maturity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=related_link\">",
"      Transvaginal cervical cerclage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_49_32533="Evaluation of male sexual dysfunction";
var content_f31_49_32533=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of male sexual dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32533/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32533/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32533/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32533/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32533/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32533/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32533/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32533/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/49/32533/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sexually competent male must have desire for his sexual partner (libido), divert blood from the iliac artery into the corpora cavernosa to achieve penile tumescence and rigidity (erection) adequate for penetration, then discharge sperm, and prostatic and seminal vesicle fluid through the urethra (ejaculation), and experience a sense of pleasure (orgasm). Impotence is defined as the inability to develop or sustain erection 75 percent of the time. It is a common abnormality and may be due to psychological causes, medications, hormonal abnormalities, neurologic, or vascular problems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following include some of the mechanisms that may be responsible for sexual dysfunction in men:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Libido declines with androgen deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/1\">",
"       1",
"      </a>",
"      ], depression [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/2\">",
"       2",
"      </a>",
"      ], and in association with the use of prescription and recreational drugs.",
"     </li>",
"     <li>",
"      Erectile dysfunction may reflect either inadequate arterial blood flow into (failure to fill) or accelerated venous drainage out of (failure to store) the corpora cavernosae.",
"     </li>",
"     <li>",
"      Disorders of ejaculation occur if the bladder neck sphincter is damaged during prostate surgery, or if alpha adrenergic impulses responsible for clamping down the bladder neck sphincter to facilitate antegrade ejaculation fail, resulting in retrograde ejaculation. Failure to ejaculate in men with adequate erectile function is also a common side effect of antidepressant medication or a reflection of an unresolved",
"      <span class=\"nowrap\">",
"       patient/partner",
"      </span>",
"      conflict. Male sexual dysfunction associated with antidepressant use is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=see_link\">",
"       \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will discuss the evaluation of the man with sexual dysfunction. The evaluation begins with a sexual history and physical examination. The history and physical examination have been reported to have a 95 percent sensitivity, but only a 50 percent specificity in determining the cause of impotence; as a result, additional diagnostic tests are needed to maximize specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/3\">",
"     3",
"    </a>",
"    ]. The normal physiology, causes, and treatment of male sexual dysfunction are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SEXUAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important information in the history includes determination of the rapidity of onset, evaluation of erectile reserve, and assessment of risk factors for impotence. This information plus nocturnal penile tumescence testing often points toward the cause of the sexual dysfunction (",
"    <a class=\"graphic graphic_table graphicRef61756 \" href=\"UTD.htm?11/45/11995\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rapidity of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually competent men who had no sexual problems until \"one night when they could not perform\" and thereafter become impotent invariably have",
"    <strong>",
"     psychogenic",
"    </strong>",
"    impotence. This problem may be caused by performance anxiety, disaffection with the current sexual partner, or some other emotional problem; psychologic counseling is the preferred therapy in this setting. Only radical prostatectomy or other overt genital tract trauma causes a sudden loss of male sexual function [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/4\">",
"     4",
"    </a>",
"    ]. In comparison, men suffering from impotence of any other cause complain that sexual function failed sporadically at first, then more consistently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Erectile reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;In men presenting with a complaint of inability to develop erections, the presence or absence of spontaneous erections is an important clue to diagnosis. Most men experience spontaneous erections during REM sleep, and often wake up with an erection, attesting to the integrity of neurogenic reflexes and corpora cavernosae blood flow. Information regarding nocturnal or early morning erections can be elicited by history from patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    partner, but proof may require nocturnal penile tumescence testing (see below). Complete loss of nocturnal erections is present in men with neurologic or vascular disease.",
"   </p>",
"   <p>",
"    Nonsustained erection with detumescence after penetration is most commonly due to anxiety or the vascular steal syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With anxiety, a conscious or subconscious concern about maintaining erectile rigidity activates an adrenergic hormone release, which is inimical to maintaining erectile turgor and rigidity. Sensate focus exercises are effective in restoring erectile confidence and competence in this setting.",
"     </li>",
"     <li>",
"      In the vascular steal syndrome, blood is diverted from the engorged corpora cavernosae to accommodate the oxygen requirements of the thrusting pelvis [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/5\">",
"       5",
"      </a>",
"      ]. Vascular surgery to ensure equitable genital and pelvic arterial inflow is obligatory [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Assessment of interpersonal conflict",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unexpressed interpersonal conflict is one of the more common, but rarely acknowledged, causes of male sexual dysfunction. Couples counseling by someone skilled in this area can restore harmony and sexual function in 25 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the basic physical examination, the evaluation of the sexually dysfunctional male should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A careful assessment of femoral and peripheral pulses as a clue to the presence of vasculogenic impotence. If pulses are normal, the presence of femoral bruits implies possible pelvic blood occlusion.",
"     </li>",
"     <li>",
"      A search for visual field defects, present in hypogonadal men with pituitary tumors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"       \"Causes of secondary hypogonadism in males\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A breast examination to detect gynecomastia, often present in Klinefelter's syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=see_link\">",
"       \"Causes and evaluation of gynecomastia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A search for penile plaques indicative of Peyronie's disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17273?source=see_link\">",
"       \"Peyronie's disease: Diagnosis and medical management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examination of the testicles looking for atrophy, asymmetry or masses.",
"     </li>",
"     <li>",
"      Evaluation of the cremasteric reflex, an index of the integrity of the thoracolumbar erection center. This is elicited by stroking the inner thighs and observing ipsilateral contraction of the scrotum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES AND DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate laboratory testing includes evaluation of hormonal function and nocturnal penile tumescence testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hormonal testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of routine measurements of serum testosterone to detect hypogonadism in men with erectile dysfunction continues to be debated [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/7\">",
"     7",
"    </a>",
"    ]. The American College of Physicians does not recommend for or against routine hormonal testing, due to insufficient evidence to determine the overall benefits versus harm [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, we do suggest measurement of serum testosterone to detect hypogonadism, because the disorder is common among older men, and symptoms alone are not reliable predictors of its presence. The prevalence of hypogonadism in men who present with erectile dysfunction varies widely across studies (from 4 to 35 percent), likely due to differences in population characteristics (such as age and co-morbidities), hormone measurement methods, or diagnostic criteria for hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 29 percent of 422 impotent men had hormonal disorders including hypogonadism in 19 percent, hyperprolactinemia in 4 percent, and either hypothyroidism or hyperthyroidism in 6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population-based study of men aged 30 to 79 years, the prevalence of a total testosterone concentration &lt;300",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      was 35 and 22.7 percent in men with and without erectile dysfunction, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in a study of 1022 men with erectile dysfunction, persistently low serum testosterone (less than 300",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [10.4",
"      <span class=\"nowrap\">",
"       nmol/L])",
"      </span>",
"      was found in only 4 percent of men under age 50, and 9 percent of those over age 50 [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/11\">",
"       11",
"      </a>",
"      ]. However, if testing had been restricted to those men with symptoms of low sexual desire or signs of hypoandrogenism, 40 percent of cases would have been missed, including 37 percent of who responded to treatment with testosterone. One percent had hyperprolactinemia. Similar results were seen in a study of 1455 men [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nocturnal penile tumescence testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPT testing, once a tedious, laborious and expensive process performed only in a hospital sleep laboratory, has been simplified. Devices such as the Rigi-Scan monitor provide accurate, reproducible information quantifying the number, tumescence and rigidity of erectile episodes a man experiences as he sleeps in the comfort of his own bed [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/14\">",
"     14",
"    </a>",
"    ]. The data generated can be downloaded to provide a graphic index quantifying erectile activity as either normal or impaired (",
"    <a class=\"graphic graphic_figure graphicRef53447 \" href=\"UTD.htm?31/42/32416\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Impotent men with normal NPT are considered to have psychogenic impotence whereas those with impaired NPT are considered to have \"organic\" impotence usually due to vascular or neurologic disease. In comparison, testosterone deficient hypogonadal men are still capable of exhibiting some erectile activity during nocturnal penile tumescence studies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/15\">",
"     15",
"    </a>",
"    ]. The mechanisms by which testosterone deficiency produces impotence is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, third party payers demanded proof of \"organic\" impotence before they would approve payment for penile prosthesis surgery. Now NPT results are used to identify men with underlying arterial or venous disorders who might benefit from corrective vascular surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Duplex Doppler imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional studies, such as duplex Doppler ultrasonography or angiography of the penile deep arteries, are indicated in men with impaired NPT to identify areas of arterial obstruction or venous leak that might be amenable to surgical reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32533/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUBSEQUENT CARDIOVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erectile dysfunction and cardiovascular disease share many risk factors and their pathophysiology is mediated through endothelial dysfunction. Underlying vascular disease is the cause of erectile dysfunction in many men. In addition, men who present with erectile dysfunction may be at higher risk for subsequent development of cardiovascular events. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with erectile dysfunction without an obvious cause (eg, pelvic trauma), and who have no symptoms of coronary or other vascular disease, should be screened for cardiovascular disease prior to initiating therapy for their sexual dysfunction, as there are potential cardiac risks associated with sexual activity in patients with heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link\">",
"     \"Sexual activity in patients with heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"     \"Screening for coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=see_link\">",
"       \"Patient information: Sex problems in men (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"       \"Patient information: Sexual problems in men (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1385890459\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Male sexual dysfunction includes erectile dysfunction, diminished libido, and abnormal ejaculation.",
"     </li>",
"     <li>",
"      Important information in the patient&rsquo;s history of erectile dysfunction includes determination of the rapidity of onset, evaluation of erectile reserve, and assessment of risk factors for impotence. This information plus nocturnal penile tumescence testing often points toward the cause of the sexual dysfunction (",
"      <a class=\"graphic graphic_table graphicRef61756 \" href=\"UTD.htm?11/45/11995\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sexual history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to the basic physical exam, there should be an assessment of secondary sexual characteristics (body hair, facial hair, body habitus) examination of femoral and peripheral pulses as a clue to the presence of vasculogenic impotence, a breast exam to look for evidence of gynecomastia, and measurement of testicular volume. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest measurement of serum testosterone to detect hypogonadism in men with erectile dysfunction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hormonal testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nocturnal penile tumescence testing can be performed to help distinguish between psychogenic and non-psychogenic causes of erectile dysfunction (such as vascular or neurologic). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Nocturnal penile tumescence testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265701\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to acknowledge the late Dr. Richard F Spark, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/1\">",
"      Bagatell CJ, Bremner WJ. Androgens in men--uses and abuses. N Engl J Med 1996; 334:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/2\">",
"      Reynolds, CF, Frank, E, Thase, ME, et al. Assessment of sexual function in depressed, impotent and healthy men. Psychiatry Res 1988; 24:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/3\">",
"      Davis-Joseph B, Tiefer L, Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology 1995; 45:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/4\">",
"      Bolt JW, Evans C, Marshall VR. Sexual dysfunction after prostatectomy. Br J Urol 1987; 59:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/5\">",
"      Michal V, Kram&aacute;r R, Posp&iacute;chal J. EXternal iliac \"steal syndrome\". J Cardiovasc Surg (Torino) 1978; 19:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/6\">",
"      Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985; 1:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/7\">",
"      Gore JL, Swerdloff RS, Rajfer J. Androgen deficiency in the etiology and treatment of erectile dysfunction. Urol Clin North Am 2005; 32:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/8\">",
"      Qaseem A, Snow V, Denberg TD, et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2009; 151:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/9\">",
"      Slag MF, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients. JAMA 1983; 249:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/10\">",
"      Spark RF, White RA, Connolly PB. Impotence is not always psychogenic. Newer insights into hypothalamic-pituitary-gonadal dysfunction. JAMA 1980; 243:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/11\">",
"      Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/12\">",
"      Earle CM, Stuckey BG. Biochemical screening in the assessment of erectile dysfunction: what tests decide future therapy? Urology 2003; 62:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/13\">",
"      Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92:4241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/14\">",
"      Bain CL, Guay AT. Reproducibility in monitoring nocturnal penile tumescence and rigidity. J Urol 1992; 148:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/15\">",
"      Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 1983; 57:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32533/abstract/16\">",
"      Lewis RW. Venous surgery for impotence. Urol Clin North Am 1988; 15:115.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7468 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32533=[""].join("\n");
var outline_f31_49_32533=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1385890459\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SEXUAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rapidity of onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Erectile reserve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Assessment of interpersonal conflict",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LABORATORY STUDIES AND DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hormonal testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nocturnal penile tumescence testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Duplex Doppler imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUBSEQUENT CARDIOVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1385890459\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H265701\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7468\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7468|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/42/32416\" title=\"figure 1\">",
"      Rigi Scan nocturnal erections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7468|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/45/11995\" title=\"table 1\">",
"      Causes male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=related_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17273?source=related_link\">",
"      Peyronie's disease: Diagnosis and medical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=related_link\">",
"      Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_49_32534="Flecainide: Pediatric drug information";
var content_f31_49_32534=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flecainide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"    see \"Flecainide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/40/4741?source=see_link\">",
"    see \"Flecainide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tambocor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Flecainide&reg;;",
"     </li>",
"     <li>",
"      Tambocor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class I-C",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12674627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Oral: Supraventricular tachycardia: Limited data available: Initial: 2 mg/kg/day divided every 12 hours; titrate to clinical response, monitor serum concentration; mean dose required to suppress SVT: 3.35 &plusmn; 1.35 mg/kg/day in 17 neonates (n=20 treated neonates; mean PNA: 11.5 days; mean GA: 36.8 weeks; mean birthweight: 2.8 kg); study did not report resultant serum concentrations;",
"     <b>",
"      Note:",
"     </b>",
"     Acute SVT was initially controlled with I.V. flecainide (not available in U.S.) and then converted to preventative oral therapy (Ferlini, 2009). In a retrospective analysis of 39 neonates treated with digoxin and/or flecainide for SVT (median PNA at treatment: 12 days), an initial flecainide dose of 6-8 mg/kg/day divided every 12 hours was used and titrated to response and serum concentrations; final dosage range of 3.2-13.5 mg/kg/day produced successful suppression of SVT in 24 of 25 patients. The authors noted high variability in serum concentrations with initial dosing (0.23-1.14 mcg/mL) (O&rsquo;Sullivan, 1995). Optimal dose not established; further studies needed.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"      see \"Flecainide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Initial: 1-3 mg/kg/day or 50-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 3 divided doses; usual: 3-6 mg/kg/day or 100-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 3 divided doses; up to 8 mg/kg/day or 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for uncontrolled patients with subtherapeutic levels; higher doses have been reported, however they may be associated with an increased risk of proarrhythmias; a review of world literature reports the average effective dose to be 4 mg/kg/day or 140 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Life-threatening ventricular arrhythmias: Initial: 100 mg every 12 hours, increase by 100 mg/day (given in 2 doses/day) every 4 days; usual: &le;300 mg/day; maximum: 400 mg/day; for patients receiving 400 mg/day who are not controlled and have trough concentrations &lt;0.6 mcg/mL, dosage may be increased to 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of paroxysmal supraventricular arrhythmias in patients with disabling symptoms but no structural heart disease: Initial: 50 mg every 12 hours; increase by 50 mg twice daily at 4-day intervals; maximum dose: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paroxysmal atrial fibrillation: Outpatient: \"Pill-in-the-pocket\" dose (for selected patients; Alboni, 2004; EHRA, 2006): 200 mg (patient weight &lt;70 kg), 300 mg (weight &ge;70 kg). May not repeat in &le;24 hours.",
"     <b>",
"      Note:",
"     </b>",
"     An initial inpatient conversion trial should have been successful before sending patient home on this approach. Patient must be taking an AV nodal-blocking agent (eg, beta-blocker, nondihydropyridine calcium channel blocker) prior to initiation of antiarrhythmic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal failure:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer recommendations: Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;35 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Initial: 50 mg every 12 hours or 100 mg once daily; increase dose slowly at intervals &gt;4 days; monitor plasma levels closely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternative adjustment: Children and Adults Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;20 mL/minute: Decrease the usual dose by 25% to 50%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as acetate: 50 mg, 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tambocor&trade;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tambocor&trade;: 100 mg, 150 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered in children and adults without regard to food; in infants receiving milk or milk based formulas, avoid concurrent administration with feedings; monitor serum concentrations and decrease the dose when the diet changes to a decreased consumption of milk",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and suppression of documented life-threatening ventricular arrhythmias (ie, sustained ventricular tachycardia); prevention of symptomatic, disabling supraventricular tachycardias in patients without structural heart disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flecainide may be confused with fluconazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tambocor&trade; may be confused with Pamelor&trade;, Temodar&reg;, tamoxifen, Tamiflu&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F171568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, palpitation, proarrhythmic, sinus node dysfunction, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, ataxia, depression, dizziness, fatigue, fever, headache, hypoesthesia, insomnia, malaise, nervousness, paresis, somnolence, tinnitus, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesias, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, alters pacing threshold, amnesia, angina, AV block, bradycardia, bronchospasm, CHF, corneal deposits, depersonalization, euphoria, exfoliative dermatitis, granulocytopenia, heart block, increased P-R, leukopenia, metallic taste, neuropathy, paradoxical increase in ventricular rate in atrial fibrillation/flutter, paresthesia, photophobia, pneumonitis, pruritus, QRS duration, swollen lips/tongue/mouth, tardive dyskinesia, thrombocytopenia, urinary retention, urticaria, ventricular arrhythmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flecainide or any component; pre-existing second or third degree A-V block; right bundle-branch block associated with left hemiblock (bifascicular block) or trifascicular block (unless a functioning pacemaker is present); cardiogenic shock, myocardial depression",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pacemakers, sick sinus syndrome, CHF, myocardial dysfunction, and renal and/or hepatic impairment; use decreased doses and cautiously titrate dose according to serum concentrations and clinical effects in patients with CHF, or myocardial, liver or renal dysfunction. Flecainide may cause increases in PR, QRS, and QT intervals and new first degree or bundle branch block; use with caution and consider dosing reduction when increases in such intervals occur.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, nonlife-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. The risks of class IC agents and the lack of improved survival make use in patients without life-threatening arrhythmias generally unacceptable.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use for symptomatic nonsustained ventricular tachycardia, frequent premature ventricular complexes (PVCs), uniform and multiform PVCs and/or coupled PVCs, or chronic atrial fibrillation is not recommended. Flecainide can worsen or cause arrhythmias with an associated risk of death",
"     <b>",
"      [U.S. Boxed Warnings]",
"     </b>",
"     . Proarrhythmic effects range from an increased number of PVCs to more severe ventricular tachycardias (ie, tachycardias that are more sustained or more resistant to conversion to sinus rhythm). Risk is reduced when lower doses were initiated; monitor and adjust dose to prevent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation. Flecainide is not recommended for patients with chronic atrial fibrillation. When treating atrial flutter, 1:1 atrioventricular conduction may occur; pre-emptive negative chronotropic therapy (eg, digoxin, beta-blockers) may lower the risk",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F171556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Flecainide. Management: Decrease flecainide dose by 50% in the presence of amiodarone.  Monitor for adverse effects of flecainide and consider monitoring for elevated serum concentrations during concomitant therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May increase the serum concentration of Flecainide.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Flecainide. Management: Concurrent use of ritonavir-boosted fosamprenavir with flecainide is contraindicated.  The use of non-ritonavir-boosted fosamprenavir with flecainide is not specifically contraindicated but should only be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: May increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Flecainide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May enhance the arrhythmogenic effect of Flecainide. Saquinavir may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Bicarbonate: May diminish the arrhythmogenic effect of Flecainide. Sodium Bicarbonate may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Lactate: May increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May enhance the adverse/toxic effect of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase the serum concentration of Flecainide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tromethamine: May increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May enhance the adverse/toxic effect of Flecainide. In particular, this combination may significantly impair myocardial contractility and AV nodal conduction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dairy products (milk, infant formula, yogurt) may interfere with the absorption of flecainide in infants; there is one case report of a neonate (GA 34 weeks PNA &gt;6 days) who required extremely large doses of oral flecainide when administered every 8 hours with feedings (&ldquo;milk feeds&rdquo;); changing the feedings from &ldquo;milk feeds&rdquo; to 5% glucose feeds alone resulted in a doubling of the flecainide serum concentration and toxicity (Russell, 1989); clearance of flecainide may be decreased in patients with strict vegetarian diets due to urinary pH &ge;8",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13386419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG, serum concentrations [",
"     <b>",
"      Note",
"     </b>",
"     : Obtain serum trough concentrations at steady state (after at least 3 days when doses are started or changed) or when dietary changes due to maturation or concurrent illness occur], liver enzymes, CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1052764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 0.2-1 mcg/mL (SI: 0.4-2 micromoles/L).",
"     <b>",
"      Note",
"     </b>",
"     : Pediatric patients may respond at the lower end of the recommended therapeutic range (0.2-0.5 mcg/mL) but up to 0.8 mcg/mL may be required.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Class IC antiarrhythmic; slows conduction in cardiac tissue by altering transport of ions across cell membranes; causes slight prolongation of refractory periods; decreases the rate of rise of the action potential without affecting its duration; increases electrical stimulation threshold of ventricle, His-Purkinje system; possesses local anesthetic and moderate negative inotropic effects",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and nearly complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 5-13.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 40% to 50% (alpha",
"     <sub>",
"      1",
"     </sub>",
"     glycoprotein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 85% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: Increased half-life with CHF or renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: &sim;29 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 11-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: &sim;20 hours (range: 12-27 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: &sim;3 hours (range: 1-6 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine as unchanged drug (10% to 50%) and metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/40/4741?source=see_link\">",
"      see \"Flecainide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dizziness; notify physician if chest pain, faintness, palpitations, dizziness or visual disturbances occur",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Single oral dose flecainide for termination of PSVT in children and young adults (n=25) and combination therapy of flecainide with amiodarone for refractory tachyarrhythmias in infancy (n=9) have been reported",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F171500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 20 mg/mL oral liquid suspension may be made from tablets and one of three different vehicles (cherry syrup, a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;, or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;). Crush twenty-four 100 mg tablets in a mortar and reduce to a fine powder. Add 20 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;protect from light&rdquo;. Stable for 60 days when stored in amber plastic prescription bottles in the dark at room temperature or refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV and Erickson III MA, &ldquo;Stability of Baclofen, Captopril, Diltiazem, Hydrochloride, Dipyridamole, and Flecainide Acetate in Extemporaneously Compounded Oral Liquids,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53:2179-84.",
"     <span class=\"pubmed-id\">",
"      8879325",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alboni P, Botto GL, Baldi N, et al, \"Outpatient Treatment of Recent-Onset Atrial Fibrillation With the 'Pill-in-the-Pocket' Approach,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(23):2384-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/49/32534/abstract-text/15575054/pubmed\" id=\"15575054\" target=\"_blank\">",
"        15575054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Fuster V, et al, \"ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation),\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/49/32534/abstract-text/16904574/pubmed\" id=\"16904574\" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fenrich AL Jr, Perry JC, and Friedman RA, &ldquo;Flecainide and Amiodarone: Combined Therapy for Refractory Tachyarrhythmias in Infants,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1995, 25(5):1195-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/49/32534/abstract-text/7897134/pubmed\" id=\"7897134\" target=\"_blank\">",
"        7897134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferlini M, Colli AM, Bonanomi C, et al, \"Flecainide as First-Line Treatment for Supraventricular Tachycardia in Newborns,\"",
"      <i>",
"       J Cardiovasc Med (Hagerstown)",
"      </i>",
"      , 2009, 10(5):372-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/49/32534/abstract-text/19300276/pubmed\" id=\"19300276\" target=\"_blank\">",
"        19300276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Musto B, Cavallaro C, Musto A, et al, &ldquo;Flecainide Single Oral Dose for Management of Paroxysmal Supraventricular Tachycardia in Children and Young Adults,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1992, 124(1):110-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/49/32534/abstract-text/1615792/pubmed\" id=\"1615792\" target=\"_blank\">",
"        1615792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Sullivan JJ, Gardiner HM, and Wren C, \"Digoxin or Flecainide for Prophylaxis of Supraventricular Tachycardia in Infants?\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1995, 26(4):991-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/49/32534/abstract-text/7560629/pubmed\" id=\"7560629\" target=\"_blank\">",
"        7560629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry JC and Garson A Jr, &ldquo;Flecainide Acetate for Treatment of Tachyarrhythmias in Children: Review of World Literature on Efficacy, Safety, and Dosing,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1992, 124(6):1614-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/49/32534/abstract-text/1462922/pubmed\" id=\"1462922\" target=\"_blank\">",
"        1462922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry JC, McQuinn RL, Smith RT Jr, et al, &ldquo;Flecainide Acetate for Resistant Arrhythmias in the Young: Efficacy and Pharmacokinetics,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1989, 14(1):185-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/49/32534/abstract-text/2500470/pubmed\" id=\"2500470\" target=\"_blank\">",
"        2500470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Priestley KA, Ladusans EJ, Rosenthal E, et al, &ldquo;Experience With Flecainide for the Treatment of Cardiac Arrhythmias in Children,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1988, 9(12):1284-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/49/32534/abstract-text/3147891/pubmed\" id=\"3147891\" target=\"_blank\">",
"        3147891",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russell GA and Martin RP, &ldquo;Flecainide Toxicity,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1989, 64(6):860-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/49/32534/abstract-text/2505692/pubmed\" id=\"2505692\" target=\"_blank\">",
"        2505692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zeigler V, Gillette PC, Ross BA, et al, &ldquo;Flecainide for Supraventricular and Ventricular Arrhythmias in Children and Young Adults,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1988, 62(10 Pt 1):818-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/49/32534/abstract-text/3138905/pubmed\" id=\"3138905\" target=\"_blank\">",
"        3138905",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13302 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32534=[""].join("\n");
var outline_f31_49_32534=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708772\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171517\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171518\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052761\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12674627\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052755\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171494\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171480\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052766\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052765\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171570\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171568\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052770\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052754\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052753\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171556\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171489\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052773\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171490\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386419\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052760\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052764\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052752\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052769\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052759\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052771\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171500\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13302\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13302|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=related_link\">",
"      Flecainide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/40/4741?source=related_link\">",
"      Flecainide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_49_32535="Anatomic boundaries of axillary lymph node dissection";
var content_f31_49_32535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Anatomic boundaries of axillary lymph node dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 468px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anatomic boundaries of axillary lymph node dissection, as seen in a transverse section through the midportion of the axilla, showing the pectoralis major and minor anteriorly, the serratus medially, and the latissimus and subscapularis posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cody H. Axillary dissection. In: Diseases of the breast, Harris, Lippman, Morrow, Osborne (Eds.), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32535=[""].join("\n");
var outline_f31_49_32535=null;
var title_f31_49_32536="Bacterial tracheitis in children: Clinical features and diagnosis";
var content_f31_49_32536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bacterial tracheitis in children: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32536/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32536/contributors\">",
"     Charles R Woods, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32536/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32536/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32536/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32536/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32536/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/49/32536/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features and diagnosis of bacterial tracheitis in children will be reviewed here. The treatment of bacterial tracheitis and tracheal infections associated with tracheostomy tubes and endotracheal intubation in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28534?source=see_link\">",
"     \"Bacterial tracheitis in children: Treatment and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2932?source=see_link\">",
"     \"Tracheal infections associated with tracheostomy tubes and endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial tracheitis is an invasive exudative bacterial infection of the soft tissues of the trachea (",
"    <a class=\"graphic graphic_picture graphicRef55364 \" href=\"UTD.htm?16/55/17264\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/1\">",
"     1",
"    </a>",
"    ]. In some cases, there is involvement of the subglottic laryngeal structures, extension into the upper bronchial tree, or associated pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Thus, \"acute bacterial laryngotracheobronchitis\" may be a more accurate clinical and anatomic description of this entity, but \"bacterial tracheitis\" is the preferred terminology in most textbooks and publications. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other terms that have been used to describe invasive exudative bacterial infection of soft tissues of the trachea include \"bacterial croup\", \"membranous croup\", \"pseudomembranous croup\", \"acute laryngotracheobronchitis\", and \"membranous laryngotracheobronchitis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The larynx of healthy individuals is often colonized with bacterial species common to the upper respiratory tract, some of which are potential pathogens (eg,",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    ,",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    , gram-negative enteric bacteria,",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    ). Such colonization can extend, at least transiently, into the trachea [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/7\">",
"     7",
"    </a>",
"    ]. Bacterial colonization of the trachea may be present within 24 hours after birth, even in infants born at &lt;31 weeks' gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacterial tracheitis almost always occurs in the setting of prior airway mucosal damage, as occurs with antecedent viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Predisposing viruses'",
"    </a>",
"    below.) Aspiration of bacteria-laden secretions into the trachea during bacterial infection of the upper respiratory tract (eg, acute bacterial sinusitis, streptococcal pharyngitis) or after tonsillectomy also may lead to bacterial tracheitis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extension of tracheal infection into the bloodstream is uncommon, as blood cultures are rarely positive [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/6,9,12-14\">",
"     6,9,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologic findings vary depending upon the combination of specific predisposing virus and bacterial etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Autopsy examinations have noted severe subglottic obstruction caused by edema, necrotic debris, and purulent secretions. The tracheal mucosa is edematous and hyperemic. Patches of mucosa may be necrotic or sloughed. Cellular infiltrates of mononuclear and polymorphonuclear cells are present in the mucosa and submucosa. Microabscesses may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hallmark exudates vary in amount and character. In mild cases, exudates may be minimal or absent. In more severe cases, exudates are extensive and sometimes so tenacious that they cannot be expectorated [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/16\">",
"     16",
"    </a>",
"    ]. The exudates may take the form of pseudomembranes that remain adherent to the tracheal lumen or become detached [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/4,12,18\">",
"     4,12,18",
"    </a>",
"    ]. Thick, inspissated mucus casts adherent to the tracheal wall also have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early on, the tracheal mucosa may appear simply red and swollen, but with untreated progression, the surfaces become covered by an exudate with a dry, glazed, gray surface that can narrow the tracheal lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/15\">",
"     15",
"    </a>",
"    ]. Marked destruction of the mucosa and deeper layers of the trachea may occur. Perforation and pneumomediastinum have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacterial tracheitis may involve the laryngeal structures, as well as the trachea. The epiglottis may be slightly erythematous but generally appears normal. The remainder of the larynx may be covered by purulent exudates, although this occurs in a minority of cases. Involvement of the mainstem bronchi is common, and exudates may extend further down into the bronchial tree [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/12,16\">",
"     12,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of bacterial tracheitis is not known, but it appears to be rare [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/20\">",
"     20",
"    </a>",
"    ]. The estimated incidence was 0.1 cases per 100,000 children per year in a multicenter review that identified 34 cases between 1993 and 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/21\">",
"     21",
"    </a>",
"    ]. Nonetheless, bacterial tracheitis is among the most frequent pediatric airway emergencies requiring admission to an intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/5,22\">",
"     5,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of cases of bacterial tracheitis occur in previously healthy children in the setting of a viral respiratory tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/6\">",
"     6",
"    </a>",
"    ]. Bacterial tracheitis generally occurs during the first six years of life (mean age in a systematic review of 300 cases ranged from 10 to 75 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/23\">",
"     23",
"    </a>",
"    ]. However, it has been reported in infants as young as one month, adolescents, and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/24\">",
"     24",
"    </a>",
"    ]. There is a slight male predominance (male-to-female ratio of 1.3:1) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of cases occur in the fall and winter, coinciding with the typical seasonal epidemics of parainfluenza, respiratory syncytial virus (RSV), and seasonal influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/1,4,9,21\">",
"     1,4,9,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link&amp;anchor=H2#H2\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology of influenza\", section on 'Seasonality'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link&amp;anchor=H6#H6\">",
"     \"Parainfluenza viruses in children\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bacterial isolates",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    is the most common bacterial isolate in nearly all case series; there are isolated reports of bacterial tracheitis caused by methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/20,21,23\">",
"     20,21,23",
"    </a>",
"    ]. Other commonly isolated bacteria include",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    , group A",
"    <em>",
"     streptococcus",
"    </em>",
"    (",
"    <em>",
"     Streptococcus pyogenes",
"    </em>",
"    ), alpha-hemolytic streptococci, and",
"    <em>",
"     Moraxella catarrhalis",
"    </em>",
"    (which is more common among younger children [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/4\">",
"     4",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    In a systematic review of 300 cases, the frequency of bacterial isolates (excluding possible contaminants such as",
"    <em>",
"     Streptococcus viridans",
"    </em>",
"    and coagulase-negative staphylococci) was as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <em>",
"       S. aureus",
"      </em>",
"      (41 percent)",
"     </li>",
"     <li>",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      (15 percent)",
"     </li>",
"     <li>",
"      <em>",
"       S. pyogenes",
"      </em>",
"      (9 percent)",
"     </li>",
"     <li>",
"      <em>",
"       M. catarrhalis",
"      </em>",
"      (12 percent)",
"     </li>",
"     <li>",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      (18 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely reported isolates include",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    ,",
"    <em>",
"     Haemophilus parainfluenzae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/6,17\">",
"     6,17",
"    </a>",
"    ],",
"    <em>",
"     Klebsiella pneumoniae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/6\">",
"     6",
"    </a>",
"    ],",
"    <em>",
"     Escherichia coli",
"    </em>",
"    ,",
"    <em>",
"     Corynebacterium",
"    </em>",
"    species (including",
"    <em>",
"     C. diphtheriae",
"    </em>",
"    ),",
"    <em>",
"     Neisseria",
"    </em>",
"    species,",
"    <em>",
"     Serratia marcescens",
"    </em>",
"    , and anaerobes, including",
"    <em>",
"     Prevotella",
"    </em>",
"    species [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/6,9,17,23,24\">",
"     6,9,17,23,24",
"    </a>",
"    ]. Bacterial tracheitis is often polymicrobial [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/2,4,5,25\">",
"     2,4,5,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are reports of cases with cultures yielding only normal oropharyngeal flora and negative cultures in patients without prior antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/2,4,24\">",
"     2,4,24",
"    </a>",
"    ]. Isolated viral infection, uncultured fastidious or anaerobic microbes, and improper specimen processing are possible explanations for such cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Predisposing viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viruses that have been isolated in children with bacterial tracheitis include influenza A, influenza B, respiratory syncytial virus (RSV), parainfluenza virus, measles, and enterovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/3,4,10,16\">",
"     3,4,10,16",
"    </a>",
"    ]. Influenza A appears to be the most commonly associated viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/4\">",
"     4",
"    </a>",
"    ]. Herpes simplex virus may predispose to and cause tracheitis, particularly in individuals who are immune compromised [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     No artificial airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two primary presentations of bacterial tracheitis have been described in children without artificial airways [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/6,17,29\">",
"     6,17,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most children, prodromal symptoms and signs suggestive of viral respiratory tract infection are present for one to three days before more severe signs of illness, such as stridor and dyspnea, develop (secondary bacterial tracheitis) [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/1,3,4\">",
"       1,3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a minority of children, onset is fulminant, with progression to acute respiratory distress less than 24 hours after the onset of initially minor symptoms (primary bacterial tracheitis). Most children with fulminant onset are toxic-appearing, with fever and leukocytosis at the time of presentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Artificial airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheal infections associated with tracheostomy tubes and endotracheal intubation in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2932?source=see_link\">",
"     \"Tracheal infections associated with tracheostomy tubes and endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant clinical features of bacterial tracheitis are those of airway obstruction: stridor, cough, and respiratory distress. Children younger than two to three years of age may be at increased risk for severe disease because of their relatively narrow airway diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/4\">",
"     4",
"    </a>",
"    ]. In children with signs of total or near-total airway obstruction, airway control precedes diagnostic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequencies of various symptoms and signs of bacterial tracheitis are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef70282 \" href=\"UTD.htm?14/7/14462\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/2,4-6,9,24\">",
"     2,4-6,9,24",
"    </a>",
"    ]. The variation of findings among the case series in the table likely reflects different combinations of antecedent viral infections and bacterial pathogens. The most frequently reported clinical features include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever (common but not universal)",
"     </li>",
"     <li>",
"      Stridor (inspiratory or expiratory)",
"     </li>",
"     <li>",
"      Cough (not painful; membranous exudates may be expectorated)",
"     </li>",
"     <li>",
"      Drooling is uncommon, but may be present",
"     </li>",
"     <li>",
"      Preference to lie flat [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Uncommon but reported symptoms and signs include neck pain, orthopnea, choking, dysphagia, dysphonia, and syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/6,14\">",
"     6,14",
"    </a>",
"    ]. Patients with significant obstruction may have cyanosis, somnolence, or combative behaviors (related to hypoxemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypercarbia) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hoarseness and wheezing, when present, usually reflect the underlying viral infection (eg, parainfluenza and respiratory syncytial virus [RSV], respectively), but occasionally may be due to bacterial infection of the laryngeal structures or extending from the trachea into the bronchial tree. Rhinorrhea, exanthems, pharyngitis, poor perfusion, erythroderma, lethargy, and other findings that represent manifestations of the associated viral infection or bacterial sepsis or toxin production also may be present.",
"   </p>",
"   <p>",
"    Toxic shock syndrome and scarlet fever have been reported in association with",
"    <em>",
"     S. aureus",
"    </em>",
"    and group A",
"    <em>",
"     streptococcus",
"    </em>",
"    bacterial tracheitis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/25,31,32\">",
"     25,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Radiographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral neck or anteroposterior radiographs typically show narrowing (steeple sign) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52418 \" href=\"UTD.htm?2/56/2959\">",
"     image 1",
"    </a>",
"    ) of the subglottic trachea that may be indistinguishable from that in viral croup. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features, evaluation, and diagnosis of croup\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Irregularity of the margins of the tracheal mucosa below the subglottis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    presence of irregular or linear shadows (membranes) in the tracheal lumen are common but not universal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80331 \" href=\"UTD.htm?33/50/34606\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/18\">",
"     18",
"    </a>",
"    ]. Serial radiographs may demonstrate change in position or disappearance of such shadows as the exudates or pseudomembranes shift position or become expectorated [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. Exudates or pseudomembranes can mimic the appearance of foreign bodies in the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/12,18,33\">",
"     12,18,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary infiltrates also are common [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/1,3,25\">",
"     1,3,25",
"    </a>",
"    ]. Atelectasis, hyperinflation, and pulmonary edema also have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither a complete blood count (CBC) with differential nor inflammatory markers are helpful in confirming or excluding the diagnosis of bacterial tracheitis. The white blood cell (WBC) count is highly variable. Mild leukopenia is as common as leukocytosis. Increased proportion of bands",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    absolute band counts are common [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/1,5,25\">",
"     1,5,25",
"    </a>",
"    ]. White blood cell count does not correlate with severity of illness or ultimate length of hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. In the only series that evaluated inflammatory markers, erythrocyte sedimentation rate or C-reactive protein were elevated in 26 of 38 patients (68 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/24\">",
"     24",
"    </a>",
"    ], but these markers are nonspecific.",
"   </p>",
"   <p>",
"    Gram stain of exudates typically shows neutrophils and may show one or more bacterial morphologies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/1,3,14,25\">",
"     1,3,14,25",
"    </a>",
"    ]. Blood cultures are rarely positive [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/6,9,12-14\">",
"     6,9,12-14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Etiologic diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial tracheitis should be suspected in children who present with acute onset of airway obstruction in the setting of viral upper respiratory infection and in children with laryngotracheitis who are febrile, toxic-appearing, and have a poor response to treatment with nebulized epinephrine or glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31144?source=see_link\">",
"     \"Approach to the management of croup\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Definitive diagnosis of bacterial tracheitis requires direct visualization of an inflamed, exudate-covered trachea (",
"    <a class=\"graphic graphic_picture graphicRef55364 \" href=\"UTD.htm?16/55/17264\">",
"     picture 1",
"    </a>",
"    ). The adjacent structures may or may not be involved. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Endoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A presumptive diagnosis can be made in children with consistent clinical and radiographic features (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80331 \" href=\"UTD.htm?33/50/34606\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/4,5,33,35\">",
"     4,5,33,35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Symptoms and signs'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Radiographic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Laboratory features (eg, white blood cell count, inflammatory markers) are not helpful in making or excluding the diagnosis. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Laboratory features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy (direct laryngoscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchoscopy) is necessary for definitive diagnosis, and possibly airway management. It is usually performed in the operating room, intensive care unit, or equivalent setting, where an artificial airway can be rapidly established if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28534?source=see_link&amp;anchor=H4#H4\">",
"     \"Bacterial tracheitis in children: Treatment and prevention\", section on 'Airway management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether every child with suspected bacterial tracheitis requires endoscopy is uncertain. Routine endoscopy was performed in some case series [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/4,6,34\">",
"     4,6,34",
"    </a>",
"    ]; in others, a subset of children were managed without endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/5\">",
"     5",
"    </a>",
"    ]. Children who require intubation based upon the severity of their clinical presentation or have progression of respiratory distress are those most likely to benefit from endoscopy.",
"   </p>",
"   <p>",
"    When endoscopy is undertaken, we suggest rigid endoscopy for suctioning of tracheal membranes and obtaining specimens for culture in children with high clinical suspicion of bacterial tracheitis and moderate to severe respiratory distress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impending airway compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/34\">",
"     34",
"    </a>",
"    ]. For children with less severe presentation, flexible endoscopy is an alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28534?source=see_link&amp;anchor=H4#H4\">",
"     \"Bacterial tracheitis in children: Treatment and prevention\", section on 'Airway management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with only minor tracheal irregularities on plain radiographs, absence of respiratory distress and hypoxia, and no other clinical indications for intubation may be initially managed without endoscopy. Such children should be closely monitored for respiratory distress and hypoxia, should the disease progress. Copious exudates or detaching pseudomembranes could obstruct the airway, necessitating intubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with bacterial tracheitis, endoscopy typically demonstrates a normal epiglottis with subglottic narrowing (edema, erythema) and thick, purulent secretions in the trachea (",
"    <a class=\"graphic graphic_picture graphicRef55364 \" href=\"UTD.htm?16/55/17264\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. Pseudomembranes may be seen, and exudate may extend into the bronchi [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/13\">",
"     13",
"    </a>",
"    ]. Membranes or thick secretions were seen in 89 percent of cases on rigid bronchoscopy in the largest modern series [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If indicated, purulent secretions and pseudomembranes can be removed during endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28534?source=see_link&amp;anchor=H7#H7\">",
"     \"Bacterial tracheitis in children: Treatment and prevention\", section on 'Endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Etiologic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specimens for Gram stain and cultures (aerobic and anaerobic) should be obtained during endoscopy or immediately following endotracheal intubation for patients requiring ventilatory support. Older patients who do not require these procedures may be able to provide a suitable sputum specimen for Gram stain and cultures.",
"   </p>",
"   <p>",
"    Tracheal or upper respiratory specimens can be sent for viral culture or rapid antigen or PCR-based tests for specific agents or panels of agents. This may provide insight into the presentation and subsequent clinical course, helping to make decisions regarding the use of antiviral therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28534?source=see_link&amp;anchor=H12#H12\">",
"     \"Bacterial tracheitis in children: Treatment and prevention\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood cultures are rarely positive in children with bacterial tracheitis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/6,9,12-14\">",
"     6,9,12-14",
"    </a>",
"    ] but should be obtained in immunocompromised children, children with signs of sepsis, or children for whom respiratory tract specimens were not obtained before initiation of antimicrobial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of bacterial tracheitis is that of acute respiratory distress, especially severe obstructive dyspnea, with fever (",
"    <a class=\"graphic graphic_table graphicRef81102 \" href=\"UTD.htm?21/10/21676\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=see_link\">",
"     \"Emergent evaluation of acute respiratory compromise in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Important considerations include epiglottitis, croup, peritonsillar or retropharyngeal abscess or cellulitis, severe bacterial pneumonia (especially with complicating parapneumonic effusion or empyema), foreign body aspiration, and diphtheria, each of which is discussed briefly below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epiglottitis &ndash; Epiglottitis may present with acute onset of upper airway obstruction, fever, and toxic appearance, similar to primary bacterial tracheitis. Children with epiglottitis classically present with dysphagia, drooling, and distress (",
"      <a class=\"graphic graphic_picture graphicRef76538 \" href=\"UTD.htm?8/0/8197\">",
"       picture 2",
"      </a>",
"      ); they prefer the tripod posture (",
"      <a class=\"graphic graphic_picture graphicRef79826 \" href=\"UTD.htm?25/54/26465\">",
"       picture 3",
"      </a>",
"      ). The presentation of bacterial tracheitis often is less acute, and drooling is uncommon, although it has been described (",
"      <a class=\"graphic graphic_table graphicRef70282 \" href=\"UTD.htm?14/7/14462\">",
"       table 1",
"      </a>",
"      ). The radiographic features of epiglottitis (enlarged epiglottis or \"thumb sign\") (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67312 \" href=\"UTD.htm?41/42/42663\">",
"       image 3",
"      </a>",
"      ) and bacterial tracheitis (normal epiglottis and intraluminal membranes) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80331 \" href=\"UTD.htm?33/50/34606\">",
"       image 2",
"      </a>",
"      ) also differ. However, tracheoscopy may be necessary for diagnosis (",
"      <a class=\"graphic graphic_picture graphicRef55364 \" href=\"UTD.htm?16/55/17264\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"       \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Croup &ndash; Bacterial tracheitis may share clinical and radiographic features with croup (viral laryngotracheitis), particularly if croup is the underlying predisposing illness. Bacterial tracheitis should be suspected as a complication of croup if there is marked worsening during the clinical course of croup (eg, high fever, toxic appearance, and increase in respiratory distress) and in children who have a poor response to nebulized epinephrine or glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical features, evaluation, and diagnosis of croup\", section on 'Bacterial tracheitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peritonsillar or retropharyngeal abscess or cellulitis &ndash; Children with peritonsillar or retropharyngeal",
"      <span class=\"nowrap\">",
"       cellulitis/abscess",
"      </span>",
"      or other painful infections of the oropharynx may present with drooling, change in voice quality, and neck extension, features that are generally (but not always) absent in children with bacterial tracheitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=see_link\">",
"       \"Peritonsillar cellulitis and abscess\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"       \"Retropharyngeal infections in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe bacterial pneumonia &ndash; Severe bacterial pneumonia, especially with complicating parapneumonic effusion or empyema, may be difficult to differentiate from bacterial tracheitis (which may extend into the lung parenchyma). Bacterial tracheitis should be suspected in children with pulmonary infiltrates who have (1) irregular tracheal markings or intratracheal opacities on plain radiographs, or (2) stridor or other signs of respiratory distress out of proportion to the lung disease apparent on plain radiographs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=see_link\">",
"       \"Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Foreign body aspiration &ndash; Foreign bodies in the larynx or trachea can cause complete or partial airway obstruction that requires immediate treatment. Foreign bodies lodged in the esophagus in the area of the cricoid cartilage or the tracheal bifurcation can compress the airway, causing partial airway obstruction. Symptoms are likely to have an abrupt onset, but in contrast to bacterial tracheitis, fever usually is absent. Tracheal foreign body and tracheal exudates or pseudomembranes may have similar appearance on radiographs [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/19,33\">",
"       19,33",
"      </a>",
"      ]. Endoscopy may be necessary to distinguish between tracheal foreign body and bacterial tracheitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"       \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diphtheria &ndash; The clinical presentation of diphtheria can be similar to that of bacterial tracheitis. The onset of symptoms is typically gradual. Sore throat, malaise, and low-grade fever are the most common presenting symptoms. A diphtheritic membrane (gray and sharply demarcated) (",
"      <a class=\"graphic graphic_picture graphicRef52701 \" href=\"UTD.htm?21/31/22003\">",
"       picture 4",
"      </a>",
"      ) may be present. Diphtheria is exceedingly rare in countries with high rates of immunization for diphtheria, tetanus, and pertussis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=see_link\">",
"       \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory bowel disease &ndash; Bacterial tracheitis rarely may mimic tracheal inflammation associated with inflammatory bowel disease. Nodular mucosal edema, small erythematous lesions, and whitish granular lesions may be seen on bronchoscopy. Infiltrations of lymphocytes and plasma cells may be seen on biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32536/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial tracheitis is an invasive exudative bacterial infection of the soft tissues of the trachea (",
"      <a class=\"graphic graphic_picture graphicRef55364 \" href=\"UTD.htm?16/55/17264\">",
"       picture 1",
"      </a>",
"      ). In some cases, there is extension to the subglottic laryngeal structures or the upper bronchial tree. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial tracheitis generally occurs during the first six years of life. The majority of cases occur in previously healthy children in the setting of a viral respiratory tract infection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      is the most common cause of bacterial tracheitis. Other commonly isolated bacteria include",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      , group A",
"      <em>",
"       streptococcus",
"      </em>",
"      (",
"      <em>",
"       Streptococcus pyogenes",
"      </em>",
"      ), alpha-hemolytic streptococci, and",
"      <em>",
"       Moraxella catarrhalis",
"      </em>",
"      . (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The predominant clinical features of bacterial tracheitis are those of airway obstruction: stridor, cough, and respiratory distress. In children with signs of total or near-total airway obstruction, airway control precedes diagnostic evaluation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Airway obstruction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"       \"Emergent evaluation of acute upper airway obstruction in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The frequencies of various symptoms and signs of bacterial tracheitis are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef70282 \" href=\"UTD.htm?14/7/14462\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic features of bacterial tracheitis may include narrowing of the subglottic trachea (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52418 \" href=\"UTD.htm?2/56/2959\">",
"       image 1",
"      </a>",
"      ), irregularity of the margins of the tracheal mucosa,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      presence of irregular or linear shadows (membranes) in the tracheal lumen (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80331 \" href=\"UTD.htm?33/50/34606\">",
"       image 2",
"      </a>",
"      ). These findings are not universal. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Radiographic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive diagnosis of bacterial tracheitis requires direct visualization of an inflamed, exudate-covered trachea (",
"      <a class=\"graphic graphic_picture graphicRef55364 \" href=\"UTD.htm?16/55/17264\">",
"       picture 1",
"      </a>",
"      ). A presumptive diagnosis can be made in children with consistent clinical and radiographic features (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80331 \" href=\"UTD.htm?33/50/34606\">",
"       image 2",
"      </a>",
"      ). Laboratory studies are not helpful in making the diagnosis, but microbiologic testing is necessary to guide antimicrobial therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of bacterial tracheitis is that of acute respiratory distress with fever. Important considerations include epiglottitis, croup, peritonsillar or retropharyngeal abscess or cellulitis, severe bacterial pneumonia, foreign body aspiration, and diphtheria (",
"      <a class=\"graphic graphic_table graphicRef81102 \" href=\"UTD.htm?21/10/21676\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=see_link\">",
"       \"Emergent evaluation of acute respiratory compromise in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"       \"Emergent evaluation of acute upper airway obstruction in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/1\">",
"      Jones R, Santos JI, Overall JC Jr. Bacterial tracheitis. JAMA 1979; 242:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/2\">",
"      Conley SF, Beste DJ, Hoffmann RG. Measles-associated bacterial tracheitis. Pediatr Infect Dis J 1993; 12:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/3\">",
"      Donnelly BW, McMillan JA, Weiner LB. Bacterial tracheitis: report of eight new cases and review. Rev Infect Dis 1990; 12:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/4\">",
"      Salamone FN, Bobbitt DB, Myer CM, et al. Bacterial tracheitis reexamined: is there a less severe manifestation? Otolaryngol Head Neck Surg 2004; 131:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/5\">",
"      Hopkins A, Lahiri T, Salerno R, Heath B. Changing epidemiology of life-threatening upper airway infections: the reemergence of bacterial tracheitis. Pediatrics 2006; 118:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/6\">",
"      Gallagher PG, Myer CM 3rd. An approach to the diagnosis and treatment of membranous laryngotracheobronchitis in infants and children. Pediatr Emerg Care 1991; 7:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/7\">",
"      Hjuler IM, Hansen MB, Olsen B, Renneberg J. Bacterial colonization of the larynx and trachea in healthy children. Acta Paediatr 1995; 84:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/8\">",
"      De Dooy J, Ieven M, Stevens W, et al. Endotracheal colonization at birth is associated with a pathogen-dependent pro- and antiinflammatory cytokine response in ventilated preterm infants: a prospective cohort study. Pediatr Res 2004; 56:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/9\">",
"      Liston SL, Gehrz RC, Siegel LG, Tilelli J. Bacterial tracheitis. Am J Dis Child 1983; 137:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/10\">",
"      Edwards KM, Dundon MC, Altemeier WA. Bacterial tracheitis as a complication of viral croup. Pediatr Infect Dis 1983; 2:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/11\">",
"      Eid NS, Jones VF. Bacterial tracheitis as a complication of tonsillectomy and adenoidectomy. J Pediatr 1994; 125:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/12\">",
"      Henry RL, Mellis CM, Benjamin B. Pseudomembranous croup. Arch Dis Child 1983; 58:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/13\">",
"      Dudin AA, Thalji A, Rambaud-Cousson A. Bacterial tracheitis among children hospitalized for severe obstructive dyspnea. Pediatr Infect Dis J 1990; 9:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/14\">",
"      Bernstein T, Brilli R, Jacobs B. Is bacterial tracheitis changing? A 14-month experience in a pediatric intensive care unit. Clin Infect Dis 1998; 27:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/15\">",
"      Orton HB, Smith EL, Bell HO, Ford RA. Acute laryngotracheobronchitis. Arch Otolaryngol 1941; 33:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/16\">",
"      Neffson AH. Acute laryngotracheobronchitis: a 25 year review. Am J Med Sci 1944; 208:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/17\">",
"      Liston SL, Gehrz RC, Jarvis CW. Bacterial tracheitis. Arch Otolaryngol 1981; 107:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/18\">",
"      Han BK, Dunbar JS, Striker TW. Membranous laryngotracheobronchitis (membranous croup). AJR Am J Roentgenol 1979; 133:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/19\">",
"      Denneny JC 3rd, Handler SD. Membranous laryngotracheobronchitis. Pediatrics 1982; 70:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/20\">",
"      Yamazaki Y, Hirai K, Honda T. Pseudomembranous tracheobronchitis caused by methicillin-resistant Staphylococcus aureus. Scand J Infect Dis 2002; 34:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/21\">",
"      Tebruegge M, Pantazidou A, Thorburn K, et al. Bacterial tracheitis: a multi-centre perspective. Scand J Infect Dis 2009; 41:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/22\">",
"      Devlin B, Golchin K, Adair R. Paediatric airway emergencies in Northern Ireland, 1990-2003. J Laryngol Otol 2007; 121:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/23\">",
"      Tebruegge M, Pantazidou A, Yau C, et al. Bacterial tracheitis - tremendously rare, but truly important: A systematic review. J Pediatr Infect Dis 2009; 4:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/24\">",
"      Huang YL, Peng CC, Chiu NC, et al. Bacterial tracheitis in pediatrics: 12 year experience at a medical center in Taiwan. Pediatr Int 2009; 51:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/25\">",
"      Kasian GF, Bingham WT, Steinberg J, et al. Bacterial tracheitis in children. CMAJ 1989; 140:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/26\">",
"      Alvarez-Uria G, Surinach JM, Ventura A, et al. Herpetic tracheitis and polybacterial pneumonia in an immunocompetent young man is herpes tracheitis involved in the pathogenesis of bacterial pneumonia? J Clin Virol 2008; 41:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/27\">",
"      McCarthy DW, Qualman SJ, Rudman DT, et al. Herpetic tracheitis and brachial plexus neuropathy in a child with burns. J Burn Care Rehabil 1999; 20:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/28\">",
"      Baras L, Farber CM, Van Vooren JP, Parent D. Herpes simplex virus tracheitis in a patient with the acquired immunodeficiency syndrome. Eur Respir J 1994; 7:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/29\">",
"      Nelson WE. Bacterial croup: a historical perspective. J Pediatr 1984; 105:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/30\">",
"      Graf J, Stein F. Tracheitis in pediatric patients. Semin Pediatr Infect Dis 2006; 17:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/31\">",
"      Surh L, Read SE. Staphylococcal tracheitis and toxic shock syndrome in a young child. J Pediatr 1984; 105:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/32\">",
"      Naqvi SH, Dunkle LM. Bacterial tracheitis and viral croup. Pediatr Infect Dis 1984; 3:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/33\">",
"      Friedman EM, Jorgensen K, Healy GB, McGill TJ. Bacterial tracheitis--two-year experience. Laryngoscope 1985; 95:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/34\">",
"      Eckel HE, Widemann B, Damm M, Roth B. Airway endoscopy in the diagnosis and treatment of bacterial tracheitis in children. Int J Pediatr Otorhinolaryngol 1993; 27:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/35\">",
"      Walner DL, Ouanounou S, Donnelly LF, Cotton RT. Utility of radiographs in the evaluation of pediatric upper airway obstruction. Ann Otol Rhinol Laryngol 1999; 108:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/36\">",
"      Kinebuchi S, Oohashi K, Takada T, et al. Tracheo-bronchitis associated with Crohn's disease improved on inhaled corticotherapy. Intern Med 2004; 43:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32536/abstract/37\">",
"      Rickli H, Fretz C, Hoffman M, et al. Severe inflammatory upper airway stenosis in ulcerative colitis. Eur Respir J 1994; 7:1899.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6034 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32536=[""].join("\n");
var outline_f31_49_32536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bacterial isolates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Predisposing viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      No artificial airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Artificial airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Radiographic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Etiologic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6034\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6034|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/56/2959\" title=\"diagnostic image 1\">",
"      Steeple sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/50/34606\" title=\"diagnostic image 2\">",
"      Bacterial tracheitis x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/42/42663\" title=\"diagnostic image 3\">",
"      Epiglottitis radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6034|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/55/17264\" title=\"picture 1\">",
"      Bacterial tracheitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/0/8197\" title=\"picture 2\">",
"      Epiglottitis classic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/54/26465\" title=\"picture 3\">",
"      Epiglottitis tripod posture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/31/22003\" title=\"picture 4\">",
"      Early diphtheritic membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6034|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/7/14462\" title=\"table 1\">",
"      Bacterial tracheitis ssx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/10/21676\" title=\"table 2\">",
"      Bacterial tracheitis DDx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31144?source=related_link\">",
"      Approach to the management of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28534?source=related_link\">",
"      Bacterial tracheitis in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=related_link\">",
"      Clinical features, evaluation, and diagnosis of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=related_link\">",
"      Emergent evaluation of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=related_link\">",
"      Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=related_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2932?source=related_link\">",
"      Tracheal infections associated with tracheostomy tubes and endotracheal intubation in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_49_32537="Achilles tendinopathy and tendon rupture";
var content_f31_49_32537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Achilles tendinopathy and tendon rupture",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32537/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32537/contributors\">",
"     Peter Ham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32537/contributors\">",
"     Karen L Maughan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32537/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32537/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32537/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32537/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/49/32537/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain of the Achilles tendon commonly affects both competitive and recreational athletes, and the sedentary. The largest tendon in the body, the Achilles tendon, endures strain and risks rupture from running, jumping, and sudden acceleration or deceleration. Overuse, vascular diseases, neuropathy, and rheumatologic diseases may cause tendon degeneration. The hallmarks of Achilles tendon problems seem to be damaged, weak, inelastic tissue.",
"   </p>",
"   <p>",
"    This topic review will discuss the mechanism, diagnosis, and management of Achilles tendinopathy and tendon rupture. A general discussion of treatments for tendinopathy is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendonitis, tendinosis, tendinopathy, paratendonitis, enthesopathy, and insertional tendonitis are among the terms used to characterize acute or chronic tendon pain. The common term tendonitis is confusing because inflammation is often not seen on histopathology. Throughout this review, we will use the term tendinopathy to refer to acute and chronic pain associated with an Achilles tendon injury other than tendon tear or rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2215?source=see_link&amp;anchor=H32168053#H32168053\">",
"     \"Overview of overuse (chronic) tendinopathy\", section on 'Pathology and terminology: tendinosis versus tendinitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achilles tendinopathy affects competitive and recreational athletes as well as people who are not active [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence of Achilles tendon rupture in the general population is 7 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Over 80 percent of ruptures occur during recreational sports. Approximately 10 percent of patients who sustain an Achilles tendon rupture had preexisting Achilles tendon problems [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational data suggest that competitive athletes have a lifetime incidence of Achilles tendinopathy of 24 percent, with 18 percent sustained by athletes younger than 45 years [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/5\">",
"     5",
"    </a>",
"    ]. Tendon rupture occurs in 8.3 percent. Among competitive runners, the lifetime incidence of Achilles tendinopathy may be as high as 40 to 50 percent.",
"   </p>",
"   <p>",
"    Competitive athletes with a high lifetime incidence of tendon rupture include sprinters (18 percent), decathletes (17 percent), soccer players (17 percent), track and field jumpers (12 percent), basketball players (12 percent), and ice hockey players (9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/5\">",
"     5",
"    </a>",
"    ]. Achilles tendinopathy in recreational runners, although less likely to involve rupture, accounts for 6 to 17 percent of all running injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/6\">",
"     6",
"    </a>",
"    ]. Military recruits develop tendinopathy at a rate of 6.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cold weather training is associated with higher rates of tendon pain [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/7\">",
"     7",
"    </a>",
"    ]. Foot misalignment, poor running mechanics (excessive supination, inadequate dorsiflexion), inappropriate footwear, and leg length discrepancy are associated with tendon pain [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age, male gender, and obesity are risk factors for Achilles tendon problems (",
"    <a class=\"graphic graphic_table graphicRef81284 \" href=\"UTD.htm?15/18/15659\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/10\">",
"     10",
"    </a>",
"    ]. The peak age for rupture is 30 to 40 years for both men and women; this may be when degenerative changes and occasional high stress from sports coincide. Rupture is four to five times more common in men than women [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/2\">",
"     2",
"    </a>",
"    ]. As participation in recreational sports has increased over the past 50 years, so has the rate of tendon rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluoroquinolone antibiotics are rarely associated with Achilles tendinopathy or tendon rupture. A study of 46,776 patients treated with fluoroquinolones found 3.2 cases of tendon problems for every 1000 years of exposure. Symptoms typically developed within one week of initiating treatment (median 6 days; range 1 to 510 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/12\">",
"     12",
"    </a>",
"    ], and the vast majority (85 to 93 percent) of patients reported symptoms within one month [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/13\">",
"     13",
"    </a>",
"    ]. Among symptomatic patients without tendon rupture, most report recovery within two months of discontinuing the fluoroquinolone antibiotic, but in 26 percent pain and disability persisted at long-term follow-up (timeframe not specified) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/12\">",
"     12",
"    </a>",
"    ]. According to a large case-control study, the incidence of tendon rupture associated with fluoroquinolone therapy is estimated at 12 per 100,000 treatment episodes (OR 1.3; 95% CI 1.0-1.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The risk of suffering an Achilles tendon rupture is increased threefold during the first 90 days among patients taking a fluoroquinolone for the first time. The mechanism remains unknown. Age older than 60 years and concurrent use of systemic glucocorticoids further increases the risk of Achilles problems [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Past fluoroquinolone use does not appear to confer future risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H29#H29\">",
"     \"Fluoroquinolones\", section on 'Tendinopathy and tendon rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral glucocorticoids alone increase the risk of tendinopathy, although studies estimating the precise risk in primary care populations are lacking. Local glucocorticoid injection causes tendon damage in animal models, and there are case reports in humans of tendon rupture following glucocorticoid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women, hypertension is associated with Achilles tendinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/10\">",
"     10",
"    </a>",
"    ]. Other diseases associated with tendinopathy include psoriasis and ankylosing spondylosis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/21\">",
"     21",
"    </a>",
"    ]. Heel pain is rarely the presenting symptom in patients with these systemic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The soleus and gastrocnemius muscles converge to form the Achilles tendon, which inserts posteriorly on the calcaneus (",
"    <a class=\"graphic graphic_figure graphicRef58376 \" href=\"UTD.htm?27/42/28326\">",
"     figure 1",
"    </a>",
"    ). Contraction of these muscles, along with the actions of the tibialis posterior and peroneus longus and brevis, causes the foot to plantar flex. The subcutaneous and subtendinous calcaneal bursae cushion the insertion area anteriorly and posteriorly. Most pain and tendon ruptures occur where the blood supply of the gastrocnemius-soleus muscle complex is poorest, 2 to 6 cm above the insertion point. A peritendinous sheath of connective tissue allows the tendon to slide relative to surrounding tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute Achilles tendon pain generally develops when athletes abruptly increase their activity (eg, runners who start training for a marathon). Chronic tendon pain (&gt;3 months) may result from sustained stress, poor running mechanics (eg, supination, heel misalignment), or improper footwear [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/11,23\">",
"     11,23",
"    </a>",
"    ]. Some experts claim a role for excessive pronation in Achilles tendinopathy among runners, but others dispute this.",
"   </p>",
"   <p>",
"    Recurrent microtrauma causes degeneration of the Achilles tendon [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/11,24\">",
"     11,24",
"    </a>",
"    ]. The relative hypovascularity of the tendon 2 to 6 cm from its insertion point may prevent adequate healing. Although inflammation is often not seen on histopathology, clinical signs similar to those seen with inflammation (such as swelling, warmth, and pain) may occur. Damaged tendons become calcified, thickened, inelastic, and fibrotic. Abnormal neovascularization of tissue may be seen on ultrasound. Aging and vascular disease decrease collagen density, break collagen cross-links, and reduce the elasticity of the tendon sheath and tendon itself. Rupture occurs when a sudden shear stress (eg, cutting during a basketball game) is applied to an already weakened or degenerative tendon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apart from Achilles tendinopathy, pain arising from the region between the posterior calcaneus and the gastrocnemius-soleus muscle complex may be caused by several other conditions (",
"    <a class=\"graphic graphic_table graphicRef76217 \" href=\"UTD.htm?34/50/35627\">",
"     table 2",
"    </a>",
"    ). Ankle sprain is the most common misdiagnosis when tendon rupture is the actual cause of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/25\">",
"     25",
"    </a>",
"    ]. Differentiating the two can be difficult. In contrast to ankle sprains, where injury occurs with landing, symptom onset with tendon rupture generally occurs as the patient is pushing off with their foot. Do NOT assume rupture is absent because the patient can plantar flex or walk. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Physical examination'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34296?source=see_link\">",
"     \"Ankle sprain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Calcaneal bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcaneal bursitis (subcutaneous or subtendinous) typically occurs in middle-aged or elderly patients. Patients may complain of pain where the back of a hard shoe or a strap rubs against the heel at the Achilles tendon insertion point. Sports in which athletes wear hard-backed footwear or repeatedly strike their heels against walls (eg, indoor soccer, hockey) may cause bursitis. Bursitis generally resolves with basic measures: heel lifts, avoiding bothersome footwear, rest, ice, and NSAIDs. Heel pain may also stem from an injury or strain at the Achilles tendon insertion (ie, enthesopathy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Calcaneal apophysitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcaneal apophysitis (ie, Sever's syndrome) is a stress fracture overuse injury in young athletes aged 8 to 15 years. Patients with calcaneal apophysitis have activity related pain in the posterior aspect of the heel, which may be unilateral or bilateral. Symptoms generally resolve within three to six weeks with conservative treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and management of heel pain in the young athlete\", section on 'Calcaneal apophysitis (Sever disease)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tendinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Achilles tendinopathy typically complain of pain or stiffness 2 to 6 cm above the posterior calcaneus. They are likely to be casual or competitive athletes who have increased their training regimen beyond their tendon's ability to heal the microtrauma from repetitive stress, or who have been training rigorously for a long time. A history of excessive supination, increased speed work or hill training, or improper or worn out footwear may be found.",
"   </p>",
"   <p>",
"    The pain is usually described as burning. The pain is worse with activity and relieved after a period of rest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tendon rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendon rupture occurs when sudden forces are exerted upon the Achilles tendon during strenuous physical activities that involve sudden pivoting on a foot or rapid acceleration (eg, stop and go sports such as tennis, basketball, or softball). Many patients feel as if they were struck violently in the back of the ankle. Some hear a \"pop\" and experience severe acute pain, although the absence of pain does not rule out rupture. As an example, a small case series found that one-third of patients with tendon rupture did not report pain [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast to ankle sprains, where injury occurs with landing, symptom onset with tendon rupture generally occurs as the patient is pushing off with their foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     General evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the Achilles tendon is usually straightforward because the tendon is easily identified and palpated. However, potential pitfalls exist (",
"    <a class=\"graphic graphic_table graphicRef70182 \" href=\"UTD.htm?0/22/363\">",
"     table 3",
"    </a>",
"    ). Of note, a sizable minority of patients with complete tendon rupture are able to ambulate.",
"   </p>",
"   <p>",
"    Patients should be examined lying prone with their feet hanging off the end of the examination table. Inspect the region of the Achilles tendon for bruising (blood tracking beneath the malleolus suggests fracture, sprain, or tendon rupture), swelling, or foot misalignment. Assess patients for signs of peripheral artery disease, such as decreased pulsations, decreased capillary refill in the heel or toes, loss of hair, increased skin pigmentation, or edema.",
"   </p>",
"   <p>",
"    Palpate the Achilles tendon for tenderness, thickening, or a defect, recognizing that edema or a hematoma may mask a defect. Patients with tendinopathy typically have localized tenderness 2 to 6 cm above the insertion point of the Achilles tendon. In comparison, pain at the insertion point suggests either calcaneal bursitis or enthesopathy (strain of tendon insertion). Palpation has a sensitivity of approximately 73 percent and specificity of 89 percent in detecting a partial tendon tear [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/26\">",
"     26",
"    </a>",
"    ]. Comparison to the unaffected side is useful.",
"   </p>",
"   <p>",
"    The tendon should also be palpated as the patient dorsi-flexes and plantar-flexes the foot. The presence of crepitus suggests tendinopathy. Isolating the subtendinous or subcutaneous bursa and palpating for tenderness may identify bursitis.",
"   </p>",
"   <p>",
"    Examine the patient's footwear, looking for signs of excessive breakdown (eg, disproportionate wear on the inner or outer edge) or other evidence of poor running mechanics. Examine the architecture of the patient's foot. The presence of flat feet (pes planus), heel malalignment, high arches (pes cavus), or leg length discrepancy can contribute to poor running mechanics [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/27\">",
"     27",
"    </a>",
"    ]. If possible, assess the patient's gait or running stride looking for abnormalities or asymmetry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Special tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calf squeeze or Thompson test provides an accurate means for detecting complete Achilles tendon rupture (",
"    <a class=\"graphic graphic_picture graphicRef74412 \" href=\"UTD.htm?36/62/37860\">",
"     picture 1",
"    </a>",
"    ). To perform the test, the patient either lies prone with their feet hanging off the end of the examination table, or kneels on a chair. The clinician squeezes the gastrocnemius muscle belly while watching for plantar flexion. The absence of plantar flexion when squeezing the gastrocnemius muscle marks a positive test indicative of rupture.",
"   </p>",
"   <p>",
"    The calf squeeze test is a more reliable indication of tendon rupture than the inability to plantar flex, since patients may be able to plantar flex the foot using accessory muscles (eg, tibialis posterior, peroneals). Twenty to 30 percent of Achilles tendon ruptures are missed at the initial visit because the clinician was falsely reassured by the patient's ability to plantar flex or walk.",
"   </p>",
"   <p>",
"    In a series of 174 patients with a clinical diagnosis of unilateral complete Achilles tendon tear and 28 patients with unilateral suspected but no actual Achilles tendon tear, the Thompson test had a sensitivity of 96 percent and a specificity of 93 percent, using MRI or ultrasound (US) as a gold standard [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/26\">",
"     26",
"    </a>",
"    ]. A negative test can miss up to 10 percent of ruptures (assuming a 75 percent pretest probability of rupture). Thus, confirmatory testing such as diagnostic ultrasound or MRI is useful when the Thompson test is negative but clinical suspicion remains high.",
"   </p>",
"   <p>",
"    The Matles test is another means of assessing Achilles tendon rupture. To perform the test, the patient lies prone with knees flexed to 90 degrees. Observe whether the affected foot is dorsiflexed or neutral (both are abnormal) compared with the uninjured side, where the foot should appear plantar-flexed. The sensitivity and specificity of the Matles test was 88 percent and 85 percent, respectively, in the above study [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achilles tendinopathy (without rupture) is a clinical diagnosis. Imaging is generally not necessary except to rule out other conditions, such as a stress fracture or tendon rupture.",
"   </p>",
"   <p>",
"    Plain radiographs are generally unhelpful in the assessment of Achilles tendon pathology, but may reveal a heel spur or bony bump (called a Haglund's deformity or \"pump bump\") consistent with both tendinopathy and calcaneal bursitis.",
"   </p>",
"   <p>",
"    Ultrasound (US) imaging is increasingly used to assess tendon appearance and function. US may reveal normal tendon, tendon thickening, or signs of more significant tendon pathology, such as neovessels, hypoechogenicity, disordered fibers, tissue gaps, and fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Achilles tendon rupture may be diagnosed solely by clinical examination, but ultrasound enables rapid bedside confirmation of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/26\">",
"     26",
"    </a>",
"    ]. Although published data is limited, in experienced hands, ultrasound appears to be an accurate tool for diagnosing Achilles tendon tear and distinguishing between partial and complete tears. As an example, ultrasound was reported to have 100 percent sensitivity, 83 percent specificity, and 92 percent accuracy for distinguishing between partial and full thickness Achilles tendon tears, using surgical findings as the gold standard [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition dynamic ultrasound can demonstrate whether tendon fragments come into contact during plantar flexion. If they do not, this is a strong indication that surgical repair is needed.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) is often used to assess musculoskeletal complaints and is the study of choice when tendon rupture is suspected and high quality diagnostic ultrasound is unavailable. MRI provides greater anatomic detail and greater accuracy in detecting partial Achilles tendon tears [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/30\">",
"     30",
"    </a>",
"    ]. With tendinopathy, MRI may demonstrate an increased T2 weighted signal in the tendon or an increased tendon diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, MRI may reveal alternative explanations for patient symptoms, such as enlarged calcaneal bursae.",
"   </p>",
"   <p>",
"    Neither US nor MRI findings appear to correlate closely with clinically significant chronic Achilles tendinopathy. In one small prospective study, US detected abnormal morphology in 37 of 57 symptomatic Achilles tendons, while MRI detected abnormalities in 19 of 34 (MRI was performed in a subset of 25 consecutive patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/32\">",
"     32",
"    </a>",
"    ]. Better baseline MRI appearance was associated with a successful return to sport and symptomatic benefit after 12 months, but baseline US findings were not. Further study of these diagnostic tests is needed to determine their appropriate role in the management of Achilles tendinopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;All complete tendon ruptures merit referral for surgical consultation. Partial tendon tears and chronic tendinopathy that fail to improve with three to six months of conservative treatment may benefit from consultation with a specialized runners' clinic, physical medicine and rehabilitation specialist, physical therapist, or orthopedic surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Tendon rupture'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute tendinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute Achilles tendinopathy generally consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoid aggravating activities",
"     </li>",
"     <li>",
"      Apply ice when symptomatic",
"     </li>",
"     <li>",
"      Take a short course (7 to 10 days) of nonsteroidal antiinflammatory drugs (NSAIDs)",
"     </li>",
"     <li>",
"      Support the Achilles with a heel lift or bandage as needed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal of therapy is to relieve symptoms and enable a return to activity. Although the approach described here appears reasonable, there is little evidence to support it.",
"   </p>",
"   <p>",
"    A systematic review of treatments for \"Achilles tendinitis\" published in 2001 identified three small controlled trials comparing oral NSAIDs to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/34\">",
"     34",
"    </a>",
"    ]. Although there is no compelling evidence that NSAIDs enable patients to return to full activity sooner, these drugs are a reasonable choice for short-term pain relief in patients with acute Achilles tendinopathy. The role of oral and topical NSAIDs in the treatment of tendinopathy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\", section on 'Anti-inflammatory medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The systematic review cited above found that injection of a glucocorticoid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    2 to 10 mg) along the tendon improves pain in the short-term, but does not appear to improve symptoms or function at 12 weeks compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In addition, there are case reports of tendon rupture after glucocorticoid injection in patients with chronic tendinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once acute healing has begun, most patients begin some form of rehabilitation. Basic therapy regimens, including such interventions as physical therapy, deep-friction tissue release, and ultrasound, may reduce symptoms over several weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients should perform an adequate warmup before and stretch following inciting activities, once these are resumed. Rehabilitation for chronic Achilles tendinopathy and prevention strategies is discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Chronic tendinopathy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Small randomized trials have found no benefit from low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    injections or heel pads, but such pads may reduce pain from calcaneal bursitis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic tendinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic Achilles tendinopathy exists when pain persists beyond three months. In addition to the basic interventions for acute exacerbations described above, treatment of chronic midportion Achilles tendon pain involves regular physical therapy, including eccentric exercise with heavy loads. A general discussion of treatments for tendinopathy is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Eccentric exercise rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eccentric exercise is the application of a load (ie, muscular exertion) during the lengthening of a muscle. Conversely, concentric exercise involves muscle shortening (or contraction) against a load. A table describing the most rigorously studied eccentric training rehabilitation protocol is provided (",
"    <a class=\"graphic graphic_table graphicRef61034 \" href=\"UTD.htm?30/45/31451\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small controlled and uncontrolled studies have found that eccentric exercise involving the gastrocnemius and soleus muscles reduces pain at 12 weeks and long-term follow-up (two to five years), and shortens the time needed to return to sports [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/6,37-40\">",
"     6,37-40",
"    </a>",
"    ]. A systematic review found there was higher quality evidence supporting the use of eccentric exercise than alternative treatments for midportion (ie, NOT insertional) Achilles tendinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/41\">",
"     41",
"    </a>",
"    ]. Ultrasound examinations during long-term follow-up of patients who participate in eccentric rehabilitation often show normalization of tendon tissue.",
"   </p>",
"   <p>",
"    Patients may perform regular exercise while participating in the eccentric rehabilitation program, provided that the activities do not exacerbate symptoms. Mild discomfort is permissible. It is not known whether eccentric exercise prevents tendon injury in runners prior to the development of tendinopathy. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various treatments have been prescribed for chronic Achilles pain. According to a systematic review, high quality evidence supporting these interventions is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/41\">",
"     41",
"    </a>",
"    ]. Some are suggested as adjuncts to eccentric exercise:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small randomized trial sponsored by the manufacturer of the AirHeel brace, use of the brace improved symptoms and function in patients with chronic Achilles tendinopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/42\">",
"       42",
"      </a>",
"      ]. The results did not differ between patients managed with the AirHeel brace or eccentric rehabilitation.",
"     </li>",
"     <li>",
"      Heel lifts, arch supports, orthotics, and running shoes that are stable and prevent oversupination are commonly prescribed, but studies supporting these interventions are lacking [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/43\">",
"       43",
"      </a>",
"      ]. Night splinting is not beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Small randomized trials suggest that low-level laser therapy is a useful adjunct to eccentric exercise, reducing pain during activity [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small randomized trial found that adjunct treatment with platelet-rich plasma injection did not improve outcomes compared with saline injection [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. Patients in both groups participated in eccentric exercise rehabilitation.",
"     </li>",
"     <li>",
"      Glucocorticoid injections are NOT recommended for chronic tendinopathy due to the risk of tendon rupture and the absence of a clear benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/1,34\">",
"       1,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Further study is needed to determine the role of shock wave therapy and topical nitrates [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/48-50\">",
"       48-50",
"      </a>",
"      ].Surgical treatment for chronic tendinopathy may be considered in refractory cases, but has not been well studied [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Tendon rupture",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9859746\">",
"    <span class=\"h3\">",
"     Initial care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of Achilles tendon rupture consists of ice applied to the area, analgesics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonsteroidal antiinflammatory drugs are generally sufficient), rest (ie, non-weightbearing with crutches), immobilization with the ankle in some plantar flexion (generally a splint is used), and referral to an orthopedic surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Complete tendon rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical consultation should be obtained for all complete Achilles tendon ruptures. The efficacy of surgery was evaluated in a systematic review of 14 randomized and quasi-randomized trials in which the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical repair reduced the risk of repeat tendon rupture compared with nonoperative management",
"      <span class=\"nowrap\">",
"       (12/240",
"      </span>",
"      (5 percent) versus",
"      <span class=\"nowrap\">",
"       30/249",
"      </span>",
"      (12 percent); risk ratio (RR) 0.41, 95% CI 0.21 to 0.77). &nbsp;",
"     </li>",
"     <li>",
"      Pooled results indicate that complications other than rerupture were reported more often in the surgically treated group, although this was not statistically significant when using the random-effects model",
"      <span class=\"nowrap\">",
"       (70/240",
"      </span>",
"      (29.2 percent) versus",
"      <span class=\"nowrap\">",
"       20/249",
"      </span>",
"      (8 percent); RR 4.81, 95% CI 0.78 to 29.56). These complications included infection, abnormal sensation (sural nerve injury), adhesions, and deep vein thrombosis.",
"     </li>",
"     <li>",
"      Although disparate outcome measures prevented the authors from pooling data, all studies but one found no significant difference in the percentage of patients treated surgically or nonoperatively who were able to return to their preinjury level of sporting activity.",
"     </li>",
"     <li>",
"      Three studies included in the review reported that percutaneous surgical repair reduced postoperative wound infections compared with open repair",
"      <span class=\"nowrap\">",
"       (0/68",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       12/66;",
"      </span>",
"      RR 9.32, 95% CI 1.77-49.16), without affecting rerupture rates. There was no significant difference in the rates of other complications.",
"     </li>",
"     <li>",
"      Assessments of recuperation time and patient satisfaction varied among studies and no clear conclusions could be drawn.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent meta-analysis of seven randomized trials reported similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/52\">",
"     52",
"    </a>",
"    ]. The rerupture rate among surgical patients in this review was 3.6 versus 8.8 percent among patients managed nonoperatively (OR 0.425; 95% CI 0.222-0.815).",
"   </p>",
"   <p>",
"    Despite the lower rerupture rates among surgical patients reported in these systematic reviews, the authors of several studies have questioned the preference for surgical repair when managing ruptured Achilles tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a controlled trial, 144 patients with acute Achilles tendon rupture were randomly assigned to operative or non-operative treatment, with both groups also undergoing accelerated rehabilitation including early weightbearing and early range of motion exercises [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/54\">",
"       54",
"      </a>",
"      ]. Although rerupture rates were comparable",
"      <span class=\"nowrap\">",
"       (2/72",
"      </span>",
"      patients in the operative group versus",
"      <span class=\"nowrap\">",
"       3/72",
"      </span>",
"      in the nonoperative group), soft tissue complications (eg, infection) occurred more often among patients treated surgically",
"      <span class=\"nowrap\">",
"       (13/72",
"      </span>",
"      [18 percent] versus",
"      <span class=\"nowrap\">",
"       6/72",
"      </span>",
"      [8 percent]). Other important clinical outcomes, including strength, motion, and overall function, were similar in both groups at one and two year follow-up.",
"     </li>",
"     <li>",
"      In a similar trial, 42 patients with acute Achilles tendon rupture were randomly assigned to surgery or no surgery, while treatment for both groups included early motion controlled in a removable orthosis, progressing to full weightbearing at eight weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/55\">",
"       55",
"      </a>",
"      ]. No differences in complications and a similar low number of re-ruptures were reported for both groups.",
"     </li>",
"     <li>",
"      In a long-term observational study not considered in either systematic review, 945 consecutive patients with both acute and delayed Achilles tendon rupture were managed with a nonsurgical approach using a structured functional rehabilitation protocol [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/53\">",
"       53",
"      </a>",
"      ]. Patients were placed initially in a non-weightbearing cast with the foot in equinus position (plantar flexion), then transitioned to a pneumatic walker with elevated heels (elevation was gradually reduced biweekly), and finally received physical therapy to improve gait, strength, and mobility. Among patients treated with this protocol, rerupture rates were reported to be low (2.8 percent in the acute tendon rupture group; 2.7 percent in the delayed rupture group) regardless of the activities that they resumed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The findings of these studies suggest that a non-operative protocol using accelerated functional rehabilitation may avoid the complications of surgical management without increasing the risk of rerupture. If additional randomized trials replicate the findings of these studies, the appropriate role of surgical and nonsurgical management will need to be reconsidered.",
"   </p>",
"   <p>",
"    Surgery typically requires two to three months off from work. Athletes typically return to sports by three to six months.",
"   </p>",
"   <p>",
"    According to a randomized trial of 110 patients with surgically repaired Achilles tendon rupture, early weightbearing starting two weeks after surgery improves quality of life scores in the early postoperative period (first six weeks) without impairing healing [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/58\">",
"     58",
"    </a>",
"    ]. At six months, quality of life scores were not different between the early mobilization and standard treatment groups.",
"   </p>",
"   <p>",
"    Nonathletes and older patients may forego surgery and elect to be treated with immobilization using a plantar flexion short leg cast or a functional brace with a heel lift for six to eight weeks. These patients should be informed of the greater risk of repeat rupture. Ideally, casting should be performed within 48 hours of injury.",
"   </p>",
"   <p>",
"    For patients who are found to have ruptured their Achilles tendon many weeks or months prior to diagnosis, immobilization with a brace followed by physical therapy is a reasonable management approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Partial tendon rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of partial Achilles tendon tear or rupture is imperfect, and studies to determine optimal management are lacking. The increasing use of ultrasound and MRI may improve this situation. It remains unclear whether surgery or conservative management leads to better outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. We treat most cases of partial Achilles tear nonsurgically, as we would chronic tendinopathy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Chronic tendinopathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of reinjury is central to follow-up care. Ten percent of Achilles tendon ruptures occur in previously injured tendons. Prevention of Achilles tendon injury is discussed immediately below.",
"   </p>",
"   <p>",
"    Although no studies demonstrate the benefit of eccentric exercise in the prevention of acute Achilles tendon injury, we suggest that patients continue to perform these exercises once rehabilitation has been completed and symptoms have resolved. We believe this may be of particular benefit to athletes embarking upon a more intense training regimen. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Chronic tendinopathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14764992\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several interventions may reduce the risk of developing new or recurrent Achilles tendinopathy, and other injuries of the lower extremity. Such interventions are discussed in detail separately. Interventions and studies of special relevance to preventing tendinopathy and tendon rupture of the Achilles are described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link&amp;anchor=H58496913#H58496913\">",
"     \"Overview of running injuries of the lower extremity\", section on 'Training suggestions to reduce injury risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before engaging in any vigorous exercise, it is important to perform an appropriate dynamic warm-up. Although few studies have assessed the Achilles tendon specifically in this regard, the findings of a prospective, observational study of infantry recruits suggest that performing such a warmup and avoiding cold weather training reduces the risk of Achilles tendinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical studies evaluating the impact of stretching specifically upon Achilles tendinopathy are lacking. Nevertheless, many clinicians believe imbalances in muscle strength or flexibility predispose some athletes to injury. We believe it is reasonable to include stretching following exercise or a warmup as part of an Achilles injury prevention regimen. Typical techniques include stretching the gastrocnemius and soleus muscles while bracing one&rsquo;s hands against a wall or dorsiflexing the foot using a stretch band. It may be helpful for patients to undergo assessment by an athletic trainer, physical therapist, or sports medicine specialist to identify imbalances in flexibility or strength and to receive instruction in appropriate training techniques.",
"   </p>",
"   <p>",
"    Although high body mass index (BMI) is associated with tendon problems, no studies clearly show that weight loss prevents such problems. Nevertheless, common sense suggests that obese patients should try to lose weight in order to reduce strain on the lower extremity, among many other health benefits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14764985\">",
"    <span class=\"h2\">",
"     Measures for patients on fluoroquinolones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of fluoroquinolone-associated tendon problems is low. However, for athletes or highly active patients who require fluoroquinolone treatment, it is reasonable to take precautions to reduce the risk of Achilles tendinopathy or tendon rupture. High quality evidence to determine what measures are most effective is lacking, but the following steps are reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32537/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beginning with the first fluoroquinolone dose, athletes should reduce their training volume and intensity and maintain these reductions throughout the course of antibiotics. No high intensity training or ballistic activities (eg, sprinting, jumping, full speed scrimmages or competition) are permitted until two to four weeks after the completion of fluoroquinolone therapy.",
"     </li>",
"     <li>",
"      Runners should decrease total mileage to 60 percent of normal training volume for the first seven days of therapy, and hill and speed interval training should be avoided. Runners who remain free of symptoms two weeks after the completion of therapy may increase mileage by 10 percent per week, but should not implement speed or hill training for two additional weeks. If they choose to race during this time they should be informed of the relatively higher risk of Achilles rupture.",
"     </li>",
"     <li>",
"      Athletes who participate in field sports (eg, soccer, football) or other multidirectional activities (eg, tennis) that increase the risk of Achilles injury may choose to resume normal activity and competition during weeks two to four after the completion of fluoroquinolone therapy. However, it is best to increase activity gradually, and athletes who resume full activity sooner than four weeks should be informed of the higher relative risk of Achilles rupture.",
"     </li>",
"     <li>",
"      Athletes who have no symptoms during therapy and complete the full course of the antibiotic can begin a graduated return to full activity as described above, but should monitor themselves closely for any musculoskeletal symptoms at or around the Achilles tendon. They should cease all athletic activity should symptoms develop during this period and be assessed by a knowledgeable clinician. Assuming there is no injury, they may resume a graduated return to full activity once symptoms resolve.",
"     </li>",
"     <li>",
"      Athletes who develop symptoms or tenderness around the Achilles while taking a fluoroquinolone antibiotic or in the first three to six months after beginning this treatment merit objective evaluation, preferably with musculoskeletal ultrasound to assess for findings of tendinopathy or other injury. Individuals with findings suggesting tendinopathy typically require an eccentric exercise rehabilitation program and possibly adjunctive therapy. Their return to play depends upon clinical response and averages 6 to 12 weeks. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Radiographic findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Eccentric exercise rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/14/17634?source=see_link\">",
"       \"Patient information: Achilles tendinopathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Presentation and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute tendon pain generally develops when athletes abruptly increase their training intensity. Chronic tendon pain (&gt;3 months) may result from sustained stress, poor running mechanics, or improper footwear. Rupture occurs when a sudden shear stress is applied to an already weakened or degenerative tendon. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanism of injury and pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain arising from the region between the posterior calcaneus and the gastrocnemius-soleus muscle complex may be caused by a number of conditions (",
"      <a class=\"graphic graphic_table graphicRef76217 \" href=\"UTD.htm?34/50/35627\">",
"       table 2",
"      </a>",
"      ). Ankle sprain is the most common misdiagnosis when tendon rupture is the actual cause of pain. Do not assume rupture is absent because the patient can plantar flex or walk. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Achilles tendinopathy typically experience pain or stiffness 2 to 6 cm above the posterior calcaneus. They are likely to be casual or competitive athletes who have recently increased their training intensity. Pain increases with activity and diminishes with a period of rest. Tendon rupture occurs when sudden forces are exerted upon the Achilles during strenuous activities that involve sudden pivoting on a foot or rapid acceleration. Patients may hear a \"pop\" and experience severe acute pain, although the absence of pain does not rule out rupture. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination should include palpation of the Achilles tendon for tenderness, thickening, or a defect. Note that edema or a hematoma may mask a defect in the tendon. Patients with tendinopathy typically have localized tenderness 2 to 6 cm above the insertion point of the Achilles tendon. Pain at the insertion point suggests calcaneal bursitis or possibly enthesopathy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The calf squeeze (ie, Thompson compression) test provides an accurate means for detecting complete Achilles tendon rupture (",
"      <a class=\"graphic graphic_picture graphicRef74412 \" href=\"UTD.htm?36/62/37860\">",
"       picture 1",
"      </a>",
"      ). A sizable minority of patients with complete tendon rupture are able to ambulate. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Achilles tendinopathy (without rupture) is a clinical diagnosis. Imaging is not generally necessary. Plain radiographs are generally unhelpful. Musculoskeletal ultrasound and magnetic resonance imaging (MRI) are accurate tests that can be used to aid in the diagnosis of Achilles tendon rupture. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment and prevention",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All complete tendon ruptures merit surgical consultation. Partial tendon tears and chronic tendinopathy that fail to improve with three to six months of conservative treatment may benefit from consultation with a specialized runners' clinic, sports medicine specialist, physical therapist, or orthopedic surgeon. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute Achilles tendinopathy is treated in standard fashion with rest, ice, and tendon support. For chronic midportion tendinopathy (&gt;3 months symptoms), we suggest rehabilitative treatment with eccentric exercise using heavy loads (",
"      <a class=\"graphic graphic_table graphicRef81284 \" href=\"UTD.htm?15/18/15659\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Eccentric exercise and other possible interventions for chronic Achilles tendinopathy are discussed in the text. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Acute tendinopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Chronic tendinopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that tendon rupture be treated with surgical repair (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). This suggestion applies to active patients who place a high value on regaining preinjury levels of activity and are willing to accept a higher rate of treatment complications. Inactive patients and those unwilling to accept higher complication rates may opt for nonoperative management. Percutaneous surgical repair may reduce postoperative wound infection rates compared with open repair. Postoperatively and in patients who opt for nonsurgical management, early mobilization and functional rehabilitation improve function and quality of life without impairing healing. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Tendon rupture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several interventions may reduce the risk of developing lower extremity injuries, including Achilles tendinopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link&amp;anchor=H58496913#H58496913\">",
"       \"Overview of running injuries of the lower extremity\", section on 'Training suggestions to reduce injury risk'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H27\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/1\">",
"      Alfredson H, Lorentzon R. Chronic Achilles tendinosis: recommendations for treatment and prevention. Sports Med 2000; 29:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/2\">",
"      Leppilahti J, Puranen J, Orava S. Incidence of Achilles tendon rupture. Acta Orthop Scand 1996; 67:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/3\">",
"      Suchak AA, Bostick G, Reid D, et al. The incidence of Achilles tendon ruptures in Edmonton, Canada. Foot Ankle Int 2005; 26:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/4\">",
"      Leppilahti J, Orava S. Total Achilles tendon rupture. A review. Sports Med 1998; 25:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/5\">",
"      Kujala UM, Sarna S, Kaprio J. Cumulative incidence of achilles tendon rupture and tendinopathy in male former elite athletes. Clin J Sport Med 2005; 15:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/6\">",
"      Fahlstr&ouml;m M, Jonsson P, Lorentzon R, Alfredson H. Chronic Achilles tendon pain treated with eccentric calf-muscle training. Knee Surg Sports Traumatol Arthrosc 2003; 11:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/7\">",
"      Milgrom C, Finestone A, Zin D, et al. Cold weather training: a risk factor for Achilles paratendinitis among recruits. Foot Ankle Int 2003; 24:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/8\">",
"      J&auml;rvinen TA, Kannus P, Paavola M, et al. Achilles tendon injuries. Curr Opin Rheumatol 2001; 13:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/9\">",
"      Leppilahti J, Korpelainen R, Karpakka J, et al. Ruptures of the Achilles tendon: relationship to inequality in length of legs and to patterns in the foot and ankle. Foot Ankle Int 1998; 19:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/10\">",
"      Holmes GB, Lin J. Etiologic factors associated with symptomatic achilles tendinopathy. Foot Ankle Int 2006; 27:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/11\">",
"      J&oacute;zsa L, Kvist M, B&aacute;lint BJ, et al. The role of recreational sport activity in Achilles tendon rupture. A clinical, pathoanatomical, and sociological study of 292 cases. Am J Sports Med 1989; 17:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/12\">",
"      van der Linden PD, van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum 2001; 45:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/13\">",
"      Akali AU, Niranjan NS. Management of bilateral Achilles tendon rupture associated with ciprofloxacin: a review and case presentation. J Plast Reconstr Aesthet Surg 2008; 61:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/14\">",
"      Sode J, Obel N, Hallas J, Lassen A. Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study. Eur J Clin Pharmacol 2007; 63:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/15\">",
"      Corrao G, Zambon A, Bert&ugrave; L, et al. Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Drug Saf 2006; 29:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/16\">",
"      van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/17\">",
"      Butler MW, Griffin JF, Quinlan WR, McDonnell TJ. Quinolone-associated tendonitis: a potential problem in COPD? Ir J Med Sci 2001; 170:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/18\">",
"      van der Linden PD, Sturkenboom MC, Herings RM, et al. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/19\">",
"      Wise BL, Peloquin C, Choi H, et al. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 2012; 125:1228.e23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/20\">",
"      Kleinman M, Gross AE. Achilles tendon rupture following steroid injection. Report of three cases. J Bone Joint Surg Am 1983; 65:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/21\">",
"      Borman P, Koparal S, Babao��lu S, Bodur H. Ultrasound detection of entheseal insertions in the foot of patients with spondyloarthropathy. Clin Rheumatol 2006; 25:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/22\">",
"      Aldridge T. Diagnosing heel pain in adults. Am Fam Physician 2004; 70:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/23\">",
"      Kaufman KR, Brodine SK, Shaffer RA, et al. The effect of foot structure and range of motion on musculoskeletal overuse injuries. Am J Sports Med 1999; 27:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/24\">",
"      Kader D, Saxena A, Movin T, Maffulli N. Achilles tendinopathy: some aspects of basic science and clinical management. Br J Sports Med 2002; 36:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/25\">",
"      Gravlee JR, Hatch RL, Galea AM. Achilles tendon rupture: a challenging diagnosis. J Am Board Fam Pract 2000; 13:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/26\">",
"      Maffulli N. The clinical diagnosis of subcutaneous tear of the Achilles tendon. A prospective study in 174 patients. Am J Sports Med 1998; 26:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/27\">",
"      Johnston CA, Taunton JE, Lloyd-Smith DR, McKenzie DC. Preventing running injuries. Practical approach for family doctors. Can Fam Physician 2003; 49:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/28\">",
"      Archambault JM, Wiley JP, Bray RC, et al. Can sonography predict the outcome in patients with achillodynia? J Clin Ultrasound 1998; 26:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/29\">",
"      Hartgerink P, Fessell DP, Jacobson JA, van Holsbeeck MT. Full- versus partial-thickness Achilles tendon tears: sonographic accuracy and characterization in 26 cases with surgical correlation. Radiology 2001; 220:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/30\">",
"      Kayser R, Mahlfeld K, Heyde CE. Partial rupture of the proximal Achilles tendon: a differential diagnostic problem in ultrasound imaging. Br J Sports Med 2005; 39:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/31\">",
"      Astr&ouml;m M, Gentz CF, Nilsson P, et al. Imaging in chronic achilles tendinopathy: a comparison of ultrasonography, magnetic resonance imaging and surgical findings in 27 histologically verified cases. Skeletal Radiol 1996; 25:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/32\">",
"      Khan KM, Forster BB, Robinson J, et al. Are ultrasound and magnetic resonance imaging of value in assessment of Achilles tendon disorders? A two year prospective study. Br J Sports Med 2003; 37:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/33\">",
"      Maffulli N, Sharma P, Luscombe KL. Achilles tendinopathy: aetiology and management. J R Soc Med 2004; 97:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/34\">",
"      McLauchlan GJ, Handoll HH. Interventions for treating acute and chronic Achilles tendinitis. Cochrane Database Syst Rev 2001; :CD000232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/35\">",
"      DaCruz DJ, Geeson M, Allen MJ, Phair I. Achilles paratendonitis: an evaluation of steroid injection. Br J Sports Med 1988; 22:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/36\">",
"      Mayer F, Hirschm&uuml;ller A, M&uuml;ller S, et al. Effects of short-term treatment strategies over 4 weeks in Achilles tendinopathy. Br J Sports Med 2007; 41:e6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/37\">",
"      Roos EM, Engstr&ouml;m M, Lagerquist A, S&ouml;derberg B. Clinical improvement after 6 weeks of eccentric exercise in patients with mid-portion Achilles tendinopathy -- a randomized trial with 1-year follow-up. Scand J Med Sci Sports 2004; 14:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/38\">",
"      Mafi N, Lorentzon R, Alfredson H. Superior short-term results with eccentric calf muscle training compared to concentric training in a randomized prospective multicenter study on patients with chronic Achilles tendinosis. Knee Surg Sports Traumatol Arthrosc 2001; 9:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/39\">",
"      Silbernagel KG, Thome&eacute; R, Thome&eacute; P, Karlsson J. Eccentric overload training for patients with chronic Achilles tendon pain--a randomised controlled study with reliability testing of the evaluation methods. Scand J Med Sci Sports 2001; 11:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/40\">",
"      van der Plas A, de Jonge S, de Vos RJ, et al. A 5-year follow-up study of Alfredson's heel-drop exercise programme in chronic midportion Achilles tendinopathy. Br J Sports Med 2012; 46:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/41\">",
"      Magnussen RA, Dunn WR, Thomson AB. Nonoperative treatment of midportion Achilles tendinopathy: a systematic review. Clin J Sport Med 2009; 19:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/42\">",
"      Petersen W, Welp R, Rosenbaum D. Chronic Achilles tendinopathy: a prospective randomized study comparing the therapeutic effect of eccentric training, the AirHeel brace, and a combination of both. Am J Sports Med 2007; 35:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/43\">",
"      Yeung EW, Yeung SS. Interventions for preventing lower limb soft-tissue injuries in runners. Cochrane Database Syst Rev 2001; :CD001256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/44\">",
"      de Vos RJ, Weir A, Visser RJ, et al. The additional value of a night splint to eccentric exercises in chronic midportion Achilles tendinopathy: a randomised controlled trial. Br J Sports Med 2007; 41:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/45\">",
"      Stergioulas A, Stergioula M, Aarskog R, et al. Effects of low-level laser therapy and eccentric exercises in the treatment of recreational athletes with chronic achilles tendinopathy. Am J Sports Med 2008; 36:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/46\">",
"      de Vos RJ, Weir A, van Schie HT, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA 2010; 303:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/47\">",
"      de Jonge S, de Vos RJ, Weir A, et al. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial. Am J Sports Med 2011; 39:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/48\">",
"      Glaser T, Poddar S, Tweed B, Webb CW. Clinical inquiries. What's the best way to treat Achilles tendonopathy? J Fam Pract 2008; 57:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/49\">",
"      Rompe JD, Furia J, Maffulli N. Eccentric loading compared with shock wave treatment for chronic insertional achilles tendinopathy. A randomized, controlled trial. J Bone Joint Surg Am 2008; 90:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/50\">",
"      Rompe JD, Furia J, Maffulli N. Eccentric loading versus eccentric loading plus shock-wave treatment for midportion achilles tendinopathy: a randomized controlled trial. Am J Sports Med 2009; 37:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/51\">",
"      Khan RJ, Carey Smith RL. Surgical interventions for treating acute Achilles tendon ruptures. Cochrane Database Syst Rev 2010; :CD003674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/52\">",
"      Wilkins R, Bisson LJ. Operative versus nonoperative management of acute Achilles tendon ruptures: a quantitative systematic review of randomized controlled trials. Am J Sports Med 2012; 40:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/53\">",
"      Wallace RG, Heyes GJ, Michael AL. The non-operative functional management of patients with a rupture of the tendo Achillis leads to low rates of re-rupture. J Bone Joint Surg Br 2011; 93:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/54\">",
"      Willits K, Amendola A, Bryant D, et al. Operative versus nonoperative treatment of acute Achilles tendon ruptures: a multicenter randomized trial using accelerated functional rehabilitation. J Bone Joint Surg Am 2010; 92:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/55\">",
"      Twaddle BC, Poon P. Early motion for Achilles tendon ruptures: is surgery important? A randomized, prospective study. Am J Sports Med 2007; 35:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/56\">",
"      Soroceanu A, Sidhwa F, Aarabi S, et al. Surgical versus nonsurgical treatment of acute Achilles tendon rupture: a meta-analysis of randomized trials. J Bone Joint Surg Am 2012; 94:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/57\">",
"      Nilsson-Helander K, Silbernagel KG, Thome&eacute; R, et al. Acute achilles tendon rupture: a randomized, controlled study comparing surgical and nonsurgical treatments using validated outcome measures. Am J Sports Med 2010; 38:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/58\">",
"      Suchak AA, Bostick GP, Beaupr&eacute; LA, et al. The influence of early weight-bearing compared with non-weight-bearing after surgical repair of the Achilles tendon. J Bone Joint Surg Am 2008; 90:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/59\">",
"      . Management of partial tears of the gastro-soleus complex. Clin Sports Med 2008; 27:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/60\">",
"      Morberg P, Jerre R, Sw&auml;rd L, Karlsson J. Long-term results after surgical management of partial Achilles tendon ruptures. Scand J Med Sci Sports 1997; 7:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32537/abstract/61\">",
"      Hall MM, Finnoff JT, Smith J. Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population. PM R 2011; 3:132.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 190 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32537=[""].join("\n");
var outline_f31_49_32537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISM OF INJURY AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Calcaneal bursitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Calcaneal apophysitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      General evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Special tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Eccentric exercise rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Other interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9859746\">",
"      - Initial care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Complete tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Partial tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14764992\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14764985\">",
"      Measures for patients on fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/190\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/190|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/42/28326\" title=\"figure 1\">",
"      Achilles tendon anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/190|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/62/37860\" title=\"picture 1\">",
"      Thompson squeeze test for Achilles tendon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/190|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/18/15659\" title=\"table 1\">",
"      Risk factors for Achilles tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/50/35627\" title=\"table 2\">",
"      Differential diagnosis of posterior heel or calf pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/22/363\" title=\"table 3\">",
"      Common pitfalls causing missed Achilles tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/45/31451\" title=\"table 4\">",
"      Alfredson's rehabilitation of Achilles tendinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34296?source=related_link\">",
"      Ankle sprain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=related_link\">",
"      Bursitis: An overview of clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28775?source=related_link\">",
"      Clinical features and management of heel pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2215?source=related_link\">",
"      Overview of overuse (chronic) tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=related_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=related_link\">",
"      Overview of the management of overuse (chronic) tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/14/17634?source=related_link\">",
"      Patient information: Achilles tendinopathy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_49_32538="Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections";
var content_f31_49_32538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32538/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32538/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32538/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32538/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/49/32538/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/49/32538/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/49/32538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of tumor necrosis factor-alpha (TNF-alpha) represent important treatment advances for a number of inflammatory conditions, including rheumatoid arthritis, the seronegative spondyloarthropathies, and inflammatory bowel disease. TNF-alpha inhibitors offer a targeted strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most forms of systemic inflammation.",
"   </p>",
"   <p>",
"    However, multiple adverse effects of TNF-alpha inhibition have been identified. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infections",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      Injection site reactions",
"     </li>",
"     <li>",
"      Infusion reactions",
"     </li>",
"     <li>",
"      Induction of autoimmunity",
"     </li>",
"     <li>",
"      Demyelinating disease",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infections associated with bacterial, viral, and fungal organisms will be reviewed here. Other major complications of TNF-alpha therapy such as tuberculosis and non-tuberculous mycobacterial infections, malignancy, the induction of autoimmunity, demyelinating disease, and heart failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2120?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The biology of TNF-alpha and some of its effects on the immune system are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TNF-ALPHA INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several inhibitors of TNF-alpha have been approved for the treatment of a variety of inflammatory illnesses (eg, rheumatoid arthritis, Crohn's disease) by the US Food and Drug Administration (FDA). These medications are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      &mdash; A chimeric",
"      <span class=\"nowrap\">",
"       (mouse/human)",
"      </span>",
"      anti-TNF-alpha monoclonal antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      &mdash; A fully human monoclonal anti-TNF-alpha antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      &mdash; A soluble TNF-alpha receptor fusion protein",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       Certolizumab pegol",
"      </a>",
"      &mdash; A pegylated Fab fragment of a humanized monoclonal antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       Golimumab",
"      </a>",
"      &mdash; A human monoclonal anti-TNF-alpha antibody",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These agents are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1711377877\">",
"    <span class=\"h1\">",
"     TNF-ALPHA AND HOST DEFENSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNF-alpha is synthesized initially by activated macrophages and T cells as a transmembrane precursor protein. The cytoplasmic tail of this protein is then cleaved to release soluble TNF-alpha. TNF-alpha is important for macrophage activation, phagosome activation, differentiation of monocytes into macrophages, recruitment of neutrophils and macrophages, granuloma formation, and maintenance of granuloma integrity [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The effects of TNF-alpha on infection have been examined in animal experiments, including models that utilize neutralizing antibodies, disrupt transcription of the gene for TNF-alpha or one of its receptors, or lead to the overexpression of soluble TNF-alpha receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/2-7\">",
"     2-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal experiments have demonstrated the importance of TNF-alpha in protection against several pathogens, including Mycobacterium tuberculosis, M. avium, M. bovis, Bacillus Calmette-Guerin (BCG), Aspergillus fumigatus, Histoplasma capsulatum, Toxoplasma gondii, Cryptococcus neoformans, and Candida albicans [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/3,5,8-10\">",
"     3,5,8-10",
"    </a>",
"    ]. These organisms are not killed readily by host defense mechanisms but rather are sequestered within granulomas, which are comprised of a central core of macrophages, multinucleated giant cells, and necrotic debris surrounded by macrophages and lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/11\">",
"     11",
"    </a>",
"    ]. TNF-alpha is required for the orderly recruitment of these cells and for continued maintenance of the granuloma structure [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11650657\">",
"    <span class=\"h1\">",
"     SCREENING FOR INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no consensus guidelines devoted to screening for infections prior to initiating a TNF-alpha inhibitor, but there is general agreement among expert panels of rheumatologists and gastroenterologists that all patients should be screened for tuberculosis, hepatitis B, and hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. An international group of gastroenterologists also advocates screening for HIV infection prior to starting a TNF-alpha inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/14\">",
"     14",
"    </a>",
"    ]. Screening for these infections is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link&amp;anchor=H15#H15\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\", section on 'Screening and prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=see_link\">",
"     \"Serologic screening for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to obtain a history of possible exposure to endemic fungi as discussed below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Histoplasmosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Coccidioidomycosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Cryptococcus'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11650707\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Rheumatology recommends that TNF-alpha inhibitors",
"    <strong>",
"     not",
"    </strong>",
"    be administered when any of the following infections are present [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active bacterial infections or bacterial infections requiring antibiotic therapy",
"     </li>",
"     <li>",
"      Active tuberculosis (TB) or untreated latent TB (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Active herpes zoster infection",
"     </li>",
"     <li>",
"      Active life-threatening fungal infections",
"     </li>",
"     <li>",
"      Severe bacterial or viral upper respiratory tract infections",
"     </li>",
"     <li>",
"      Non-healed infected skin ulcers",
"     </li>",
"     <li>",
"      Acute hepatitis B or C infection",
"     </li>",
"     <li>",
"      Chronic hepatitis B or C infection (treated or untreated) with significant liver injury, defined as chronic Child-Pugh classes B or C (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=see_link\">",
"       calculator 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We agree with these recommendations. If a TNF-alpha inhibitor is started in a patient with chronic hepatitis B, antiviral therapy for hepatitis B should be given. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Hepatitis B'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Decisions about the appropriate timing for initiating a TNF-alpha inhibitor following resolution of the infections described above should be made on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSESSING INFECTIOUS RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmarketing surveillance and observational studies provided the first indications that TNF-alpha inhibitors are associated with an increased risk of serious infections [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Data from individual randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/20-27\">",
"     20-27",
"    </a>",
"    ] and large observational studies have been inconsistent on this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/28-31\">",
"     28-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several potential explanations for the failure of clinical trials to detect an increased risk of infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relatively small numbers of patients are enrolled in any given trial.",
"     </li>",
"     <li>",
"      Clinical trials tend to enroll patients who are healthy relative to patients with the same disease who are not enrolled in trials.",
"     </li>",
"     <li>",
"      Follow-up periods in many clinical trials are relatively short, with the longest follow-up in most trials of biologic agents in rheumatoid arthritis (RA) being one year or less.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The limitation of small numbers of patients was addressed in a systemic review and meta-analysis of randomized clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    (the two monoclonal antibody TNF-alpha inhibitors) that included 3493 patients who received TNF-alpha inhibitors and 1512 who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/32\">",
"     32",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pooled odds ratio (OR) for serious infection among patients treated with a TNF-alpha inhibitor was 2.0 (95% CI 1.3-3.1).",
"     </li>",
"     <li>",
"      The number needed to harm with a serious infection within three to twelve months of treatment was 59 (95% CI 39-125).",
"     </li>",
"     <li>",
"      Twelve of the 126 serious infections were granulomatous in nature, including 10 cases of tuberculosis and one each of histoplasmosis and coccidioidomycosis. Exclusion of these infections from the analysis still yielded an OR of 1.9 (95% CI 1.2-2.9) for serious infection among patients treated with TNF-alpha inhibitors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increased risk of infection was also noted in an observational study from a German registry in which 512 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and 346 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    were followed for up to one year [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/28\">",
"     28",
"    </a>",
"    ]. Controls (n = 601) were recruited if they had failed therapy with a disease modifying antirheumatic drug (DMARD), and were starting a second DMARD rather than a TNF-alpha inhibitor. The registry data included viral and fungal infections, tuberculosis (TB), and bacterial infections.",
"   </p>",
"   <p>",
"    The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The numbers of serious infections per 100 patient-years among patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      were 6.4 (95% CI 4.5-9.1) and 6.2 (95% CI 4.0-9.5), respectively, compared with 2.3 (95% CI 1.3-3.9) for those treated with conventional DMARDs.",
"     </li>",
"     <li>",
"      In multivariate analyses that adjusted for disease duration, number of prior therapies, number of involved joints, disease activity scores, and other relevant variables, the adjusted relative risk of a severe or moderately severe infection compared to conventional DMARDs was 3.0 for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (95% CI 1.8-5.1) and 2.3 for the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      group (95% CI 1.4-3.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective cohort study of veterans in the United States with rheumatoid arthritis, TNF-alpha antagonist use (hazard ratio [HR] 1.24, 95% CI 1.02-1.50) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    use (HR 2.14, 95% CI 1.88-2.43) were associated with hospitalization for infection, whereas the use of DMARDs other than TNF-alpha antagonists was not [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/29\">",
"     29",
"    </a>",
"    ]. The most common infections were pneumonia, bronchitis, and cellulitis. Compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    was associated with an increased risk for hospitalization for infection (HR 1.51, 95% CI 1.14-2.00), whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    was not.",
"   </p>",
"   <p>",
"    In contrast, in a retrospective cohort study of patients in the United States with rheumatoid arthritis (RA), inflammatory bowel disease, psoriasis, psoriatic arthritis, or ankylosing spondylitis, no increase in the risk of hospitalization for infection was observed in patients initiating treatment with a TNF-alpha inhibitor compared with nonbiologic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/30\">",
"     30",
"    </a>",
"    ]. Among patients with RA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    was associated with an increase in serious infections compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (adjusted HR [aHR] 1.26, 95% CI 1.07-1.47) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    (aHR 1.23, 95% CI 1.02-1.48). An accompanying editorial pointed out that possible reasons for the lack of difference in the risk of hospitalization include multiple potential confounders in both treatment groups, as well as the possibility that the infection rate in the comparator group may be higher than in prior studies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data from individual randomized clinical trials and a cohort study failed to demonstrate a consistent increase in treatment-related infections, data from the meta-analysis of randomized clinical trials, the German registry, and another cohort study are consistent with the concept that TNF-alpha inhibitor use is associated with an increased risk of serious infection. The impact of TNF-alpha inhibitors on the risk of particular types of infection is discussed below.",
"   </p>",
"   <p>",
"    The FDA has stated that patients receiving a TNF-alpha inhibitor who are greater than 65 years of age or who are taking concomitant immunosuppressants may be at greater risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TUBERCULOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to latent and active tuberculosis (TB) and to prophylaxis against active TB in patients on TNF-alpha inhibitors are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BACTERIAL INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk of bacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of bacterial infection with anti-TNF-alpha therapy was evaluated in a retrospective cohort study of rheumatoid arthritis (RA) patients in the United States enrolled in a large health care organization who had received either a TNF-alpha inhibitor or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/35\">",
"     35",
"    </a>",
"    ]. Seventy percent of the patients treated with a TNF-alpha inhibitor were also treated with MTX.",
"   </p>",
"   <p>",
"    The focus of this study was on bacterial infections in hospitalized patients. Corresponding medical records were abstracted and reviewed by infectious disease experts. Data from 2393 patients treated with TNF-alpha inhibitors and 2933 patients treated with MTX were evaluated.",
"   </p>",
"   <p>",
"    The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of hospitalization with a confirmed bacterial infection was 2.7 percent among patients treated with TNF-alpha inhibitors either alone or in combination with MTX, compared with 2.0 percent for patients treated with MTX alone.",
"     </li>",
"     <li>",
"      In multivariate analysis, the hazard ratio for bacterial infection was 1.9 (95% CI 1.3-2.8) compared with patients who received only MTX.",
"     </li>",
"     <li>",
"      The incidence of infections was highest within six months after the initiation of TNF-alpha inhibitor therapy, with an adjusted hazard ratio of 4.2 (95% CI 2.0-8.8) for patients receiving a TNF-alpha inhibitor compared to those receiving MTX alone. Those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      were at greater risk of developing infection than those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to common bacterial infections, unusual bacterial pathogens have also been reported to cause disease in patients on TNF-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/19\">",
"     19",
"    </a>",
"    ]. In general, the reports of such occurrences are sporadic and it is not clear if targeted TNF-alpha inhibition truly constitutes a predisposing factor. However, because of the pleiotropic effects of TNF-alpha on host defense, some contribution of targeted TNF-alpha inhibition to the occurrence of such events is biologically plausible. An example of this is listeriosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1210178637\">",
"    <span class=\"h2\">",
"     Septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The British Society for Rheumatology Biologics Register, a prospective observational study of patients with rheumatoid arthritis, compared the risk of septic arthritis in 11,881 patients who received a TNF-alpha inhibitor and 3673 patients who received nonbiological disease-modifying antirheumatic drugs (DMARDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/37\">",
"     37",
"    </a>",
"    ]. One hundred seventy-nine patients who received a TNF-alpha inhibitor had at least one episode of septic arthritis compared with 20 patients who received DMARDs. The adjusted hazard ratio for septic arthritis in patients who received a TNF-alpha inhibitor was 2.3 (95% CI 1.2-4.4). The risk was highest in the early months following initiation of TNF-alpha inhibitor therapy and did not differ based upon which TNF-alpha inhibitor was used.",
"   </p>",
"   <p>",
"    Staphylococcus aureus was the most common cause of septic arthritis in both cohorts, occurring in 57 percent of patients who received a TNF-alpha inhibitor and 43 percent of patients who received DMARDs. In the patients who received a TNF-alpha inhibitor, several cases were caused by organisms that rarely cause septic arthritis, including five cases caused by intracellular pathogens (three cases caused by Salmonella spp and two cases caused by Listeria spp) and four cases caused by Pseudomonas aeruginosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Listeriosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Listeria monocytogenes is a gram-positive intracellular bacterium that is associated most often with meningoencephalitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    septicemia. The disease is linked to the ingestion of contaminated dairy and meat products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Listeriosis has been described in patients receiving TNF-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/18,34,38-40\">",
"     18,34,38-40",
"    </a>",
"    ], and in 2011, the FDA added a boxed warning about the risk of listeriosis for the entire class of TNF-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/34\">",
"     34",
"    </a>",
"    ]. In a report on granulomatous infectious diseases from the US Food and Drug Administration (FDA) Adverse Events Reporting System (AERS) from 1998 to 2002, there were 38 cases of Listeria infection: 36 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and two with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (15.5 versus 1.8 per 100,000 patients, a difference that was highly significant) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/18\">",
"     18",
"    </a>",
"    ]. A search of the medical literature in 2011 identified 26 published cases of listeriosis in patients who had received a TNF-alpha inhibitor, including seven deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9993?source=see_link\">",
"     \"Epidemiology and pathogenesis of Listeria monocytogenes infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The acquisition of Listeria through the ingestion of contaminated foods emphasizes the importance of educating patients regarding food preparation and safety. Preventive measures to minimize the risk of foodborne Listeria infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\", section on 'Prevention of foodborne infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1446752307\">",
"    <span class=\"h2\">",
"     Legionella pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, the FDA added a boxed warning about the risk of Legionella infection for the entire class of TNF-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/34\">",
"     34",
"    </a>",
"    ]. This warning was issued because an increased risk of Legionella infection was detected among patients who had received a TNF-alpha inhibitor. Between 1999 and 2010, 80 cases of Legionella pneumonia, including four deaths, were reported to the FDA&rsquo;s Adverse Events Reporting System in patients receiving a TNF-alpha inhibitor. An additional 23 cases were published in the medical literature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32680?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and pathogenesis of Legionella infection\", section on 'Host risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Legionella infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33015?source=see_link\">",
"     \"Treatment and prevention of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other bacterial infections preferentially associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    included nocardiosis, nontuberculous mycobacteria, and, as noted above, tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     VIRAL INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, there are few data related to the impact of TNF-alpha inhibitor use among human patients with viral infections. However, the effects of TNF-alpha inhibition upon the course of viral infections may vary according to the specific type of viral infection. As an example, inhibition of TNF-alpha appears to delay the clearance of hepatitis B, but may attenuate hepatic injury with hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential exists for reactivation of certain viral infections by anti-TNF-alpha therapy either directly due to lack of TNF-alpha or indirectly via effects on T cell activation and interferon production. This appears most relevant in the case of hepatitis B, an intracellular infection that is controlled by cytokine and cellular mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/41,42,44\">",
"     41,42,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several reports of stable hepatitis B virus infections that were reactivated during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. In some patients, serum aminotransferase concentrations increased after infliximab withdrawal, reminiscent of an immune reconstitution inflammatory syndrome (IRIS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American College of Rheumatology recommends that TNF-alpha inhibitors be avoided in patients with acute hepatitis B infection or with chronic hepatitis B infection (treated or untreated) with significant liver injury, defined as chronic Child-Pugh classes B or C (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11650707\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the magnitude of this risk is uncertain, we favor antiviral therapy of hepatitis B in HBsAg positive patients starting a TNF-alpha inhibitor. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link&amp;anchor=H6#H6\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\", section on 'Crohn's disease treated with infliximab or adalimumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link&amp;anchor=H7#H7\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\", section on 'Rheumatalogic disorders treated with anti-TNF agents, methotrexate, and other biologics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link&amp;anchor=H18#H18\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deleterious effects on hepatitis C appear unusual with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/50-57\">",
"     50-57",
"    </a>",
"    ]. One randomized, placebo-controlled trial of etanercept as adjunctive therapy to IFN-alpha plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    found that etanercept improved the virologic response rate and decreased the rate of adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/58\">",
"     58",
"    </a>",
"    ]. Despite this observation, data relating to the use of TNF-alpha inhibitors in the setting of hepatitis C infections are limited, and monitoring of serum aminotransferases is advised if a TNF-alpha inhibitor is used in such patients.",
"   </p>",
"   <p>",
"    The American College of Rheumatology recommends that TNF-alpha inhibitors be avoided in patients with acute hepatitis C infection or with chronic hepatitis C infection (treated or untreated) with significant liver injury, defined as chronic Child-Pugh classes B or C (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11650707\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Herpes zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of herpes zoster in patients with underlying autoimmune diseases (eg, rheumatoid arthritis, inflammatory bowel disease), particularly in those receiving immunosuppressive therapies including glucocorticoids and disease-modifying antirheumatic drugs (DMARDs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\", section on 'Autoimmune disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are conflicting data regarding the question of whether TNF-alpha inhibitors confer a greater risk of herpes zoster compared with other therapies for autoimmune diseases. The largest study to address this issue was a multicenter cohort study performed in the United States, which compared the incidence of herpes zoster in 33,324 patients initiating a TNF-alpha inhibitor and 25,742 patients initiating nonbiologic DMARDs; underlying diseases included rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, and ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/59\">",
"     59",
"    </a>",
"    ]. Patients who initiated a TNF-alpha inhibitor were not at higher risk for herpes zoster than patients initiating nonbiologic DMARDs and no differences in risk were observed among",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    . A large retrospective study of patients with rheumatoid arthritis also showed that TNF-alpha inhibitors increased the risk of herpes zoster to a similar degree as other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in a prospective cohort study that included 5040 patients with rheumatoid arthritis, after adjustment for age, disease severity, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    use, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    was associated with a moderately increased risk of herpes zoster (hazard ratio 1.82, 95% CI 1.05-3.15) compared with nonbiologic DMARDs [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/61\">",
"     61",
"    </a>",
"    ]. There was a trend towards an increased risk with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , although it did not achieve statistical significance.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Human immunodeficiency virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several case reports describing the use of TNF-alpha inhibitors to treat rheumatoid arthritis or other inflammatory conditions in the setting of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In general, these reports suggest that TNF-alpha inhibition can be tolerated well by HIV-infected patients, provided that treatment of HIV is well established before initiation of therapy with a TNF-alpha inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other viral infections, such as those caused by cytomegalovirus, herpes simplex virus [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/64\">",
"     64",
"    </a>",
"    ] and molluscum contagiosum, have been reported to occur in patients treated with TNF-alpha inhibitors, but the true nature of the association between these infections and TNF-alpha inhibition is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FUNGAL INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The critical role of TNF-alpha in granuloma formation and its other contributions to host defense make granulomatous infections an anticipated complication of TNF-alpha inhibitors. Data from human studies have confirmed the heightened risk of granulomatous infections, including fungal infections, associated with TNF-alpha inhibitor use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link&amp;anchor=H4#H4\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'TNF-alpha and host defenses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to fungal infections usually associated with granulomatous inflammation, cases of Pneumocystis pneumonia (PCP) have also been reported among patients treated with targeted TNF-alpha inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Granulomatous infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungi such as Histoplasma capsulatum and Coccidioides immitis are found readily in the environment in endemic areas. Both reactivation of latent disease and new infections with histoplasmosis and coccidioidomycosis have been described with the use of TNF-alpha inhibitors, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=see_link\">",
"     \"Coccidioidomycosis in compromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2008, the US Food and Drug Administration (FDA) issued a warning about the risk for pulmonary and disseminated histoplasmosis, coccidioidomycosis, blastomycosis, and other invasive fungal infections in patients undergoing treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or other TNF-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/68\">",
"     68",
"    </a>",
"    ]. The warning is based on reports of 240 cases of histoplasmosis in patients treated with TNF-alpha inhibitors. In at least 21 of these reports, histoplasmosis was not recognized initially, which led to a delay in antifungal therapy; there were 12 fatal outcomes.",
"   </p>",
"   <p>",
"    Clinicians should have a high index of suspicion for invasive fungal infections, particularly in patients who live in or have traveled to endemic regions, and investigate for these infections and treat promptly. Typical signs and symptoms of histoplasmosis and other invasive fungal infections include fever, malaise, weight loss, sweats, cough, dyspnea, pulmonary infiltrates on x-ray, or serious systemic illness including shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Histoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasma capsulatum is acquired through inhalation of mycelial fragments and microconidia, typically from soil. Cases are often associated with exposure to bird roosts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ten cases of H. capsulatum infections were reported in the US FDA Adverse Events Reporting System (AERS) from the late 1990s through July 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/69\">",
"     69",
"    </a>",
"    ]. Up until approximately the same time, 79 cases of tuberculosis were reported to AERS [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/70\">",
"     70",
"    </a>",
"    ]. As of September 2008, 240 cases of histoplasmosis associated with TNF-alpha inhibitor use have been reported to AERS [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings were noted in an analysis of histoplasmosis cases [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nine of the 10 cases occurred in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , and one with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The number of cases attributable to acute infections as opposed to either reactivation of latent disease or reinfection was not clear.",
"     </li>",
"     <li>",
"      All 10 patients resided in areas in which H. capsulatum is endemic, and all 10 had received immunosuppressive agents other than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In the cases associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , symptoms of infection presented within one week to six months of the first dose. In comparison, the case associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      use occurred after 11 months of treatment.",
"     </li>",
"     <li>",
"      Clinical manifestations typically included fever, malaise, cough, dyspnea, and interstitial pneumonitis.",
"     </li>",
"     <li>",
"      Nine of the 10 patients required treatment in the intensive care unit. One patient died.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among 19 patients who presented to the Indiana University Medical Campus with histoplasmosis while receiving a TNF-alpha inhibitor between 2000 and 2009, most were receiving additional immunosuppressive medications [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/71\">",
"     71",
"    </a>",
"    ]. Seventeen patients (89 percent) presented with a progressive febrile illness consistent with progressive disseminated histoplasmosis. Pulmonary involvement was present in 15 patients (79 percent) and was a prominent feature in 13 (68 percent). Fifteen patients (79 percent) required hospitalization, and four (21 percent) developed respiratory failure and shock. All 19 patients recovered.",
"   </p>",
"   <p>",
"    A higher incidence of histoplasmosis after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    was noted in a follow-up study of 42 histoplasmosis cases reported to the AERS between 1998 and 2002: 39 were associated with infliximab use and three with etanercept [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/18\">",
"     18",
"    </a>",
"    ]. The annual rate of infection among patients treated with infliximab was 17 per 100,000 infliximab-treated patients, a rate that far exceeds the national rate and was significantly higher than the rate of histoplasmosis after etanercept (3 per 100,000 etanercept-treated patients).",
"   </p>",
"   <p>",
"    Screening for histoplasmosis involves questioning TNF-alpha inhibitor candidates about potential exposures with specific reference to high-risk activities (eg, demolition of old buildings, cleaning chicken coops, spelunking) in endemic areas and symptoms of active or recent histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/71\">",
"     71",
"    </a>",
"    ]. Areas of endemicity include parts of the midwestern United States, Mexico, Central and South America, Africa, and Asia. In patients with a history of high-risk activities, symptoms of active histoplasmosis, or a history of histoplasmosis within the past two years, a chest radiograph should be obtained. The routine use of Histoplasma serologies or antigen testing is not recommended for screening; however these tests are indicated as part of the diagnostic evaluation in patients suspected of having histoplasmosis. The diagnosis and treatment of histoplasmosis are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The FDA suggests that clinicians consider discontinuing the TNF-alpha inhibitor in patients who develop histoplasmosis or other invasive fungal infections during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/68\">",
"     68",
"    </a>",
"    ]. However, some patients have experienced a paradoxical clinical worsening following discontinuation of the TNF-alpha inhibitor despite evidence of improvement of the fungal infection; such a pattern is suggestive of an immune reconstitution inflammatory syndrome (IRIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/71\">",
"     71",
"    </a>",
"    ]. Further study is necessary to establish the role of IRIS in such patients, as well as to determine the optimal management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Coccidioidomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidioides immitis is a dimorphic fungus endemic to the southwestern United States and parts of Central and South America. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=see_link\">",
"     \"Coccidioidomycosis in compromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are limited data on the occurrence, prophylaxis, and management of C. immitis infections among patients treated with TNF-alpha inhibitors. In a study of patients from clinics in endemic areas in California, Arizona, and Nevada, the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirteen cases were reported; 12 were associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and one was associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      . Two of the infections were believed to be reactivation of previous coccidioidal infections",
"     </li>",
"     <li>",
"      Among the 247 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and the 738 patients treated with other therapies for inflammatory arthritis, the rate of symptomatic coccidioidomycosis over the five-year observation period was significantly higher with infliximab (2.8 versus 0.5 percent, relative risk 5.2, 95% CI 1.5-17.7).",
"     </li>",
"     <li>",
"      Eleven of the 12 patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      were also receiving MTX, and two were also taking additional immunosuppressive medications.",
"     </li>",
"     <li>",
"      All 13 patients had pneumonia at presentation, and four had documented dissemination of the C. immitis infection to the blood, spleen, peritoneum, or central nervous system.",
"     </li>",
"     <li>",
"      Two patients died (one from staphylococcal line sepsis during the course of C. immitis therapy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In areas in which C. immitis is endemic, recommendations prior to the institution of a TNF-alpha inhibitor include a chest radiograph and coccidioidal serologic tests for IgM and IgG. However, baseline testing may be of limited utility because, as shown in the prior study, most coccidioidomycosis cases after anti-TNF-alpha therapy represent acute infection rather than reactivation.",
"   </p>",
"   <p>",
"    The possible role of antifungal prophylaxis to prevent coccidioidal infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=see_link&amp;anchor=H15#H15\">",
"     \"Coccidioidomycosis in compromised hosts\", section on 'Glucocorticoid and immunosuppressive therapies for autoimmune diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Cryptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcus neoformans is an encapsulated fungus that is distributed worldwide. The organism is found typically in soil and in high concentrations near bird roosts. Inhalation of the organism frequently occurs after disruption of soil. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=see_link\">",
"     \"Microbiology and epidemiology of cryptococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In animal models of Cryptococcus infection, TNF-alpha inhibition is associated with impaired recruitment of activated CD4+ T cells and Langerhans cells to the area of infection and an increased risk of dissemination [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/8,73\">",
"     8,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryptococcal infections were described in 19 patients reported to the US FDA AERS system between 1998 and 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/18\">",
"     18",
"    </a>",
"    ]. Eleven of those patients had received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , and eight had received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (4.7 and 7.1 infections per 100,000 treated patients, respectively, a difference that was not significantly different). Most patients in this report and others were receiving additional immunosuppressive agents, particularly MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/74-76\">",
"     74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with AIDS who have experienced cryptococcal infections, secondary prophylaxis is recommended until immune reconstitution occurs. We suggest considering this strategy in patients receiving TNF-alpha inhibitors who have a history of cryptococcal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23929?source=see_link&amp;anchor=H7361640#H7361640\">",
"     \"Treatment of cryptococcal meningoencephalitis in HIV-infected patients\", section on 'Primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus species (eg, A. fumigatus) are ubiquitous environmental fungi capable of causing a wide variety of diseases in both healthy and immunocompromised hosts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TNF-alpha inhibition may increase the risk of aspergillosis through the inhibition of neutrophil recruitment. Case reports and small cases series exist of A. fumigatus infections associated with TNF-alpha inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/18,77\">",
"     18,77",
"    </a>",
"    ]. However, the interpretation of many cases is complicated by the simultaneous use of several immunosuppressive agents.",
"   </p>",
"   <p>",
"    Aspergillosis was noted in 39 patients in the AERS report cited above: 29 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and 10 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (12.4 versus 8.8 per 100,000 patients, a difference that was not significant) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pneumocystis pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review from the FDA Adverse Event Reporting System (AERS) from 1998 to 2003 included 84 patients with pneumocystis pneumonia (PCP) associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    use [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/65\">",
"     65",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean time between the first",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      infusion and the onset of PCP symptoms was 21 days.",
"     </li>",
"     <li>",
"      Death occurred in 23 of the 84 patients (27 percent).",
"     </li>",
"     <li>",
"      Concomitant immunosuppressive medications included",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , 6-mercaptopurine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      doses and CD4 lymphocyte counts at the time of PCP infection were not reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a case-control study, risk factors for PCP in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    included older age, coexisting pulmonary disease, and high doses of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/78\">",
"     78",
"    </a>",
"    ]. Because the risk of PCP correlates with high-dose glucocorticoid use in some studies, PCP prophylaxis should be considered among patients treated with TNF-alpha inhibitors if they are also receiving high-dose glucocorticoids or other intensive immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OTHER INFECTION ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted by the preceding findings, there is clear evidence for an increased risk of a variety of infections among patients treated with TNF-alpha inhibitors. However, the risk of these infections must be interpreted in the context of the potential benefits and of the possible adverse effects of conventional therapies. The decision to use an anti-TNF-alpha agent is an individual one, based upon the specific clinical features and unique risk profile of a given patient.",
"   </p>",
"   <p>",
"    Patients should be educated about the importance of recognizing symptoms and signs of infections, particularly fever, because of the heightened risk of these complications and the greater likelihood of disseminated infections among immunocompromised hosts. Patients with symptoms or signs of infections should be evaluated without delay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Timing of infection risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data indicate that the risk of infection associated with TNF-alpha inhibitor use is highest in the period shortly after the initiation of therapy. In an analysis of the British Society for Rheumatology Biologics Register [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/80\">",
"     80",
"    </a>",
"    ], the adjusted incidence ratio for infection was not elevated for patients receiving TNF-alpha inhibitors compared with those on DMARDs alone (ratio 1.22, 95% CI 0.88-1.69). However, when the analysis was limited to the first 90 days of follow-up after the initiation of a new therapy, the adjusted incidence rate ratio was 4.6 (95% CI 1.8-11.9) among patients treated with TNF-alpha inhibitors.",
"   </p>",
"   <p>",
"    Increased risk of tuberculosis in the period immediately following the institution of TNF-alpha inhibition has also been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link&amp;anchor=H10#H10\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\", section on 'Risk with different agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Perioperative use of TNF-alpha inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of TNF-alpha inhibitors has been associated with an increased risk of perioperative infections. This issue was addressed in a series of 91 RA patients who underwent orthopedic procedures between 1999 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/81\">",
"     81",
"    </a>",
"    ]. All procedures involved instrumentation into a joint space, dissection into bone, or both. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ten of the 91 patients developed a serious postoperative orthopedic infection.",
"     </li>",
"     <li>",
"      Seven of the 10 patients (70 percent) who suffered orthopedic infections were receiving TNF-alpha inhibitors at the time of their surgery, compared with 28 of the 81 (35 percent) patients who remained infection free.",
"     </li>",
"     <li>",
"      The increased risk of infection with TNF-alpha inhibitor use at the time of surgery was statistically significant after adjustment for age, sex,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      use, diabetes, and rheumatoid factor status (odds ratio 5.3, 95% CI 1.1-24.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major weakness of this study was the potential for confounding by indication, in which the prescription of a TNF-alpha inhibitor was a surrogate marker for patients with the most active or severe disease and therefore for the subset of patients at highest risk of infection. These findings need to be confirmed in prospective studies that also address the appropriate duration of abstinence from TNF-alpha inhibitor use before and after surgery",
"   </p>",
"   <p>",
"    Given the available data, it is reasonable to consider discontinuing TNF-alpha inhibitors for several weeks before orthopedic surgery. However, the potential benefit of preventing some postoperative infections must be balanced against the risk of a perioperative flare in RA activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Combination therapy with anakinra",
"    </span>",
"    &nbsp;&mdash;&nbsp;A higher rate of serious infections has been observed in patients receiving the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    (a recombinant human interleukin 1 receptor antagonist) compared with trials of either agent alone [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/82\">",
"     82",
"    </a>",
"    ]. The use of TNF-alpha inhibitors in combination with anakinra is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vaccines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157888956\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should ensure that patients are up to date on vaccinations before starting a course of TNF-alpha inhibition. Initiation of TNF-alpha inhibitor therapy should be delayed after administration of a live organism vaccine, as discussed below. (See",
"    <a class=\"local\" href=\"#H157888984\">",
"     'Live virus vaccines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All patients receiving TNF-alpha inhibitors should be vaccinated against pneumococcus and should receive the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    annually; those with specific risk factors should also be vaccinated against hepatitis B (",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/13,83\">",
"     13,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other vaccines not containing live organisms should be given according to the routine schedule (",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157888963\">",
"    <span class=\"h3\">",
"     Pneumococcal vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 23-valent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) has been recommended for immunocompromised adults in the United States for many years, but in 2012, the United States Advisory Committee on Immunization Practices (ACIP) began recommending",
"    <strong>",
"     both",
"    </strong>",
"    PPSV23 and the 13-valent conjugate pneumococcal vaccine (PCV13) for immunocompromised adults (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"UTD.htm?11/48/12046\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In accordance with the ACIP, we recommend that individuals receiving a TNF-alpha inhibitor receive PCV13 in addition to PPSV23 as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have not previously received either PCV13 or PPSV23, a single dose of PCV13 should be given, followed by a dose of PPSV23 at least eight weeks later.",
"     </li>",
"     <li>",
"      For patients who have previously received one or more doses of PPSV23, a single dose of PCV13 should be given one or more years after the last PPSV23 dose was received.",
"     </li>",
"     <li>",
"      For patients who require additional doses of PPSV23, the first such dose should be given no sooner than eight weeks after PCV13 and at least five years after the most recent dose of PPSV23.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H157888984\">",
"    <span class=\"h3\">",
"     Live virus vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccines containing live organisms should",
"    <strong>",
"     not",
"    </strong>",
"    be administered during treatment with TNF-alpha inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link&amp;anchor=H23747684#H23747684\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\", section on 'Patients with rheumatic and inflammatory bowel diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initiation of TNF-alpha inhibitor therapy should be delayed after administration of a live organism vaccine. Following administration of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     herpes zoster vaccine",
"    </a>",
"    , the ACIP recommends waiting at least 14 days before initiation of immunosuppressive therapy, although some experts recommend waiting for one month [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/85\">",
"     85",
"    </a>",
"    ]. Guidelines have not been developed regarding the waiting period between the administration of other live organism vaccines and the initiation of immunosuppressive therapy. However, it is reasonable to extrapolate from recommendations for solid organ transplant candidates or blood donors. The American Society of Transplantation recommends waiting a minimum of four weeks between live virus vaccine administration and transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/86\">",
"     86",
"    </a>",
"    ]. The American Association of Blood Banks has published guidelines regarding the timing of blood donation following the receipt of live organism vaccines; they recommend a two- to four-week waiting period depending on the type of vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?31/49/32538/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link&amp;anchor=H3#H3\">",
"     \"Immunizations in solid organ transplant candidates and recipients\", section on 'Timing of immunizations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link&amp;anchor=H5#H5\">",
"     \"Blood donor medical history\", section on 'Recent vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor necrosis factor (TNF)-alpha inhibitor use is associated with an increased risk of serious infections. The increase in risk is seen with a variety of infections, including tuberculosis (TB) and bacterial, viral, and fungal infections. This risk must be interpreted in the context of the potential benefits and of the possible adverse effects of conventional therapies.(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Assessing infectious risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to initiating a TNF-alpha inhibitor, all patients should be screened for tuberculosis, hepatitis B, and hepatitis C. Some experts also favor screening for HIV infection. It is also important to obtain a history of possible exposure to endemic fungi. (See",
"      <a class=\"local\" href=\"#H11650657\">",
"       'Screening for infections'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link&amp;anchor=H15#H15\">",
"       \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\", section on 'Screening and prevention'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Granulomatous infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TNF-alpha inhibitors should",
"      <strong>",
"       not",
"      </strong>",
"      be administered when any of the following infections are present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Active bacterial infections or bacterial infections requiring antibiotic therapy",
"     </li>",
"     <li>",
"      Active tuberculosis or untreated latent TB (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Active herpes zoster infection",
"     </li>",
"     <li>",
"      Active life-threatening fungal infections",
"     </li>",
"     <li>",
"      Severe bacterial or viral upper respiratory tract infections",
"     </li>",
"     <li>",
"      Non-healed infected skin ulcers",
"     </li>",
"     <li>",
"      Acute hepatitis B or C infection",
"     </li>",
"     <li>",
"      Chronic hepatitis B or C infection (treated or untreated) with significant liver injury, defined as chronic Child-Pugh classes B or C (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H11650707\">",
"       'Contraindications'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of the risk of listeriosis, patients on TNF-alpha inhibitors should follow recommendations to avoid foodborne infections. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bacterial infections'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\", section on 'Prevention of foodborne infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is a risk of hepatitis B virus (HBV) reactivation in patients with previous HBV infections. We suggest antiviral therapy of hepatitis B in HBsAg positive patients starting a TNF-alpha inhibitor. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hepatitis B'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TNF-alpha inhibition use may be safe in patients infected with the hepatitis C virus, but there remain limited data on this point. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hepatitis C'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is an increased risk of herpes zoster in patients with underlying autoimmune diseases, particularly among those receiving immunosuppressive therapies including glucocorticoids and disease-modifying antirheumatic drugs (DMARDs). However, the risk of herpes zoster in patients receiving a TNF-alpha inhibitor does not appear to be higher than in patients receiving nonbiologic DMARDs. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Herpes zoster'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TNF-alpha inhibition use in patients infected with HIV may be safe, provided that the patient is on an effective HIV treatment regimen. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Human immunodeficiency virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Case series of histoplasmosis, coccidioidomycosis, cryptococcosis, and other invasive fungal infections indicate an increased risk through either new infections or reactivation of latent ones. Physicians caring for patients in regions that are endemic for deep fungal infections must maintain a high degree of suspicion for the occurrence of such complications. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Fungal infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cases of Pneumocystis pneumonia (PCP) have been reported among patients treated with TNF-alpha inhibitors. We suggest considering PCP prophylaxis in patients treated with TNF-alpha inhibitors who are also receiving other immunosuppressive medications, particularly high-dose glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Discontinuing TNF-alpha inhibitors for several weeks before patients undergo orthopedic surgery is reasonable. However, if the decision is made to discontinue a TNF-alpha inhibitor before a surgical procedure, close monitoring of the patient for an RA flare is necessary. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Perioperative use of TNF-alpha inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of a TNF-alpha inhibitor and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      (a recombinant human interleukin 1 receptor antagonist) is not recommended, because of an increased risk of infection. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Combination therapy with anakinra'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should ensure that patients are up to date on vaccinations before starting a course of TNF-alpha inhibition. Live vaccines should",
"      <strong>",
"       not",
"      </strong>",
"      be administered to patients receiving therapy with a TNF-alpha inhibitor. Initiation of TNF-alpha inhibitor therapy should be delayed after administration of a live organism vaccine. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Vaccines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/1\">",
"      Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am 2010; 24:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/2\">",
"      Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/3\">",
"      Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 1998; 160:6072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/4\">",
"      Garcia I, Miyazaki Y, Marchal G, et al. High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas. Eur J Immunol 1997; 27:3182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/5\">",
"      Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/6\">",
"      Benini J, Ehlers EM, Ehlers S. Different types of pulmonary granuloma necrosis in immunocompetent vs. TNFRp55-gene-deficient mice aerogenically infected with highly virulent Mycobacterium avium. J Pathol 1999; 189:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/7\">",
"      Bopst M, Garcia I, Guler R, et al. Differential effects of TNF and LTalpha in the host defense against M. bovis BCG. Eur J Immunol 2001; 31:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/8\">",
"      Huffnagle GB, Toews GB, Burdick MD, et al. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 1996; 157:4529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/9\">",
"      Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A 1997; 94:8093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/10\">",
"      Mehrad B, Strieter RM, Standiford TJ. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999; 162:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/11\">",
"      Randhawa PS. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 1990; 22:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/12\">",
"      Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/13\">",
"      Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2011; 70 Suppl 1:i2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/14\">",
"      D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/15\">",
"      Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/16\">",
"      Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003; 42:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/17\">",
"      G&oacute;mez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/18\">",
"      Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/19\">",
"      Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005; 84:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/20\">",
"      Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/21\">",
"      St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/22\">",
"      Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/23\">",
"      Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/24\">",
"      van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003; 62:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/25\">",
"      Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/26\">",
"      Solomon DH, Lunt M, Schneeweiss S. The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence. Arthritis Rheum 2008; 58:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/27\">",
"      Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/28\">",
"      Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/29\">",
"      Lane MA, McDonald JR, Zeringue AL, et al. TNF-&alpha; antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore) 2011; 90:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/30\">",
"      Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-&alpha; antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/31\">",
"      Keystone EC. Does anti-tumor necrosis factor-&alpha; therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol 2011; 38:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/32\">",
"      Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/33\">",
"      Dixon W, Felson DT. Is anti-TNF therapy safer than previously thought? JAMA 2011; 306:2380.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: drug labels for the tumor necrosis factor-alpha (TNF&alpha;) blockers now include warnings about infection with Legionella and Listeria bacteria. file://www.fda.gov/Drugs/DrugSafety/ucm270849.htm (Accessed on September 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/35\">",
"      Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/36\">",
"      Curtis JR, Xi J, Patkar N, et al. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56:4226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/37\">",
"      Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/38\">",
"      Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/39\">",
"      Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56:2563.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Listeriosis. file://www.cdc.gov/listeria/ (Accessed on October 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/41\">",
"      Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/42\">",
"      Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A 1994; 91:3764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/43\">",
"      Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997; 42:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/44\">",
"      Pasquetto V, Wieland SF, Uprichard SL, et al. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 2002; 76:5646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/45\">",
"      Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/46\">",
"      Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/47\">",
"      Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/48\">",
"      Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/49\">",
"      Esteve M, Saro C, Gonz&aacute;lez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/50\">",
"      del Valle Garc&iacute;a-S&aacute;nchez M, G&oacute;mez-Camacho F, Poyato-Gonz&aacute;lez A, et al. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/51\">",
"      Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/52\">",
"      Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/53\">",
"      Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/54\">",
"      Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/55\">",
"      Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001; 13:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/56\">",
"      Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003; 98:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/57\">",
"      Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011; 50:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/58\">",
"      Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/59\">",
"      Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/60\">",
"      McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/61\">",
"      Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/62\">",
"      Kaur PP, Chan VC, Berney SN. Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. J Clin Rheumatol 2007; 13:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/63\">",
"      Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/64\">",
"      Bradford RD, Pettit AC, Wright PW, et al. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis 2009; 49:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/65\">",
"      Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007; 52:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/66\">",
"      Seddik M, Meliez H, Seguy D, et al. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2004; 10:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/67\">",
"      Wallis RS, Broder M, Wong J, et al. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005; 41 Suppl 3:S194.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration MedWatch. file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124185.htm (Accessed on October 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/69\">",
"      Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/70\">",
"      Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/71\">",
"      Hage CA, Bowyer S, Tarvin SE, et al. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis 2010; 50:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/72\">",
"      Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004; 50:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/73\">",
"      Bauman SK, Huffnagle GB, Murphy JW. Effects of tumor necrosis factor alpha on dendritic cell accumulation in lymph nodes draining the immunization site and the impact on the anticryptococcal cell-mediated immune response. Infect Immun 2003; 71:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/74\">",
"      True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol 2002; 29:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/75\">",
"      Shrestha RK, Stoller JK, Honari G, et al. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir Care 2004; 49:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/76\">",
"      Hage CA, Wood KL, Winer-Muram HT, et al. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 2003; 124:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/77\">",
"      Warris A, Bj&oslash;rneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/78\">",
"      Harigai M, Koike R, Miyasaka N, Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007; 357:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/79\">",
"      Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/80\">",
"      Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56:2896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/81\">",
"      Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006; 55:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/82\">",
"      Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002; 65:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/83\">",
"      Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/84\">",
"      Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/85\">",
"      Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/49/32538/abstract/86\">",
"      Danzinger-Isakov L, Kumar D, AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 Suppl 4:S258.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Guidance for Industry: Acceptable full-length donor history questionnaire and accompanying materials for use in screening human donors of blood and blood components. file://www.fda.gov/cber//blood/bldguid.htm (Accessed on October 06, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1410 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32538=[""].join("\n");
var outline_f31_49_32538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TNF-ALPHA INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1711377877\">",
"      TNF-ALPHA AND HOST DEFENSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11650657\">",
"      SCREENING FOR INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11650707\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSESSING INFECTIOUS RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TUBERCULOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BACTERIAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk of bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1210178637\">",
"      Septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Listeriosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1446752307\">",
"      Legionella pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      VIRAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Human immunodeficiency virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FUNGAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Granulomatous infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Cryptococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pneumocystis pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OTHER INFECTION ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Timing of infection risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Perioperative use of TNF-alpha inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Combination therapy with anakinra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H157888956\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H157888963\">",
"      - Pneumococcal vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H157888984\">",
"      - Live virus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1410\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1410|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42263\" title=\"figure 1\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1410|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/48/12046\" title=\"table 1\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=related_link\" title=\"calculator 1\">",
"      Calculator: Child Pugh classification for severity of liver disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=related_link\">",
"      Blood donor medical history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=related_link\">",
"      Clinical manifestations and diagnosis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=related_link\">",
"      Clinical manifestations and diagnosis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21848?source=related_link\">",
"      Coccidioidomycosis in compromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32680?source=related_link\">",
"      Epidemiology and pathogenesis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9993?source=related_link\">",
"      Epidemiology and pathogenesis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=related_link\">",
"      Microbiology and epidemiology of cryptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=related_link\">",
"      Pathogenesis and clinical manifestations of disseminated histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/15/33015?source=related_link\">",
"      Treatment and prevention of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23929?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=related_link\">",
"      Treatment, prognosis, and prevention of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2120?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_49_32539="ICU admission for withdrawal";
var content_f31_49_32539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested criteria for intensive care unit admission of patients with alcohol withdrawal",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Age &gt;40",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cardiac disease (heart failure, arrhythmia, angina, myocardial ischemia, recent myocardial infarction)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hemodynamic instability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Marked acid-base disturbances",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe electrolyte defects (hypokalemia, hypophosphatemia, hypomagnesemia, hypocalcemia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory insufficiency (hypoxemia, hypercapnia, severe hypocapnia, pneumonia, asthma, COPD)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Potentially serious infections (wounds, pneumonia, trauma, urinary tract infection)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Signs of gastrointestinal pathology (pancreatitis, GI bleeding, hepatic insufficiency, suspected peritonitis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Persistent hyperthermia (T &gt;39&deg;C [103&deg;F])",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Evidence of rhabdomyolysis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Renal insufficiency or increased fluid requirements",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       History of prior alcohol withdrawal complications (eg, delirium tremens, alcohol withdrawal seizures)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Need for frequent or high doses of sedatives or an intravenous infusion to control symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Withdrawal despite an elevated ethanol concentration",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Carlson, RW, Keske, B, Cortez, D, J Crit Illness 1998; 13:311.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32539=[""].join("\n");
var outline_f31_49_32539=null;
var title_f31_49_32540="Essential features TL receptors";
var content_f31_49_32540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Essential features of the toll-like receptors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Receptor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ligands",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cell expression",
"       </td>",
"       <td class=\"subtitle1\">",
"        Signaling intermediates",
"       </td>",
"       <td class=\"subtitle1\">",
"        Products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR1+ TLR2",
"       </td>",
"       <td>",
"        Triacyl lipopeptide (Gram+ bacteria, mycobacteria), Neisseria porins, B. burgdorferi OspA",
"       </td>",
"       <td>",
"        M/M, MDC",
"       </td>",
"       <td>",
"        TIRAP, MyD88",
"       </td>",
"       <td>",
"        IC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR2+ TLR6",
"       </td>",
"       <td>",
"        Diacyl lipopeptide",
"       </td>",
"       <td>",
"        M/M, MC",
"       </td>",
"       <td>",
"        TIRAP, MyD88",
"       </td>",
"       <td>",
"        IC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR3",
"       </td>",
"       <td>",
"        dsRNA (viruses)",
"       </td>",
"       <td>",
"        B, T, NK",
"       </td>",
"       <td>",
"        TRIF",
"       </td>",
"       <td>",
"        IC, type I IFN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR4",
"       </td>",
"       <td>",
"        LPS (Gram- bacteria), RSV fusion protein, Chlamydia hsp60, extracellular matrix",
"       </td>",
"       <td>",
"        M/M, MDC, MC",
"       </td>",
"       <td>",
"        TRAM, TRIF or TIRAP, MyD88",
"       </td>",
"       <td>",
"        IC, type I IFN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR5",
"       </td>",
"       <td>",
"        Flagellin (bacteria)",
"       </td>",
"       <td>",
"        M/M, MDC",
"       </td>",
"       <td>",
"        MyD88",
"       </td>",
"       <td>",
"        IC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR7",
"       </td>",
"       <td>",
"        ssRNA (viruses), imidazoquinolines",
"       </td>",
"       <td>",
"        M/M, MDC, PDC, B",
"       </td>",
"       <td>",
"        MyD88",
"       </td>",
"       <td>",
"        IC, type I IFN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR8",
"       </td>",
"       <td>",
"        ssRNA (viruses), imidazoquinolines",
"       </td>",
"       <td>",
"        M/M, MDC, MC",
"       </td>",
"       <td>",
"        MyD88",
"       </td>",
"       <td>",
"        IC, type I IFN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR9",
"       </td>",
"       <td>",
"        CpG DNA (bacteria)",
"       </td>",
"       <td>",
"        M/M, PDC, B, T",
"       </td>",
"       <td>",
"        MyD88",
"       </td>",
"       <td>",
"        IC, type I IFN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TLR10",
"       </td>",
"       <td>",
"        (unknown)",
"       </td>",
"       <td>",
"        M/M, B",
"       </td>",
"       <td>",
"        MyD88",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IC: inflammatory cytokines including TNF, IL-1beta, IL-6, IL-12; LPS: lipopolysaccharide; CpG DNA: cytosine guanine dinucleotide motifs (in bacterial DNA); OspA: outer surface protein A; M/M: macrophage/monocytel; MDC: myeloid dendritic cell; PDC: plasmacytoid dendritic cell; MC: mast cell; B: B cell; T: T cell; NK: natural killer cell; TIRAP: TIR domain-containing adapter protein; MyD88: myeloid differentiation primary response protein 88; TRIF: TIR domain-containing adapter inducing IFN beta; TRAM: TRIF-related adapter molecule.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32540=[""].join("\n");
var outline_f31_49_32540=null;
var title_f31_49_32541="Proinsulin in prolonged fast";
var content_f31_49_32541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasma proinsulin concentrations after a prolonged fast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 279px; background-image: url(data:image/gif;base64,R0lGODlh7gAXAeYAAP///yBzOf8AAICAgAAAABBsNkBAQMDAwICzmQAzGTAwMCAgIKCgoBAQEHBwcFBQUNDQ0PDw8ODg4GBgYJCQkLCwsP+/v//w8P8QEP9/f8fczf8/P/+wsP8wMP9gYP/Q0P9QUP+goP8gII+5nP+vr//g4P+QkP9wcP/f31eWav/v7//Pz/9AQP/AwMDZzf9PT/9fX+Pt5v+Pj/+AgGWedhBwQBhvN53BqP8vLwJmMw5rNf8fH7nTwQhpNPH28nCpjeDs5gBmMwZoNC17RRxxODCDWUCMZtXk2f8PD/D28xZuNwRnMx5yOFCWc7DQwEmNXqvKtGCggApqNKDGs3Ong/9vbxRuNgxqNYGwjxJtNtDj2f+fn5C8piB5TRpwN4CZjIBDKUBZTa8fD+8GA3+DaTuEUQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADuABcBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMMHy8uMDAYQixETBg6DEszNABIUAxQRh9rYEpcR2QfJxwTr64wDBOiKEwQODIPv7ASCBuwKh+0A3g24dCCfPkYFB6artY4ZgAMDKlCrIAjCAwP84gmK4MDAhGgHFhAYQE4QtgMOCCwQVCFCBJEaBwEUCICjx2gB7eXMCUGhoIIKHD4z8IAiAAoYHUiYZ8DnwljrBgyw964BPwISJDRoMCAjIQVcwUpg0IAANEMidQ4SWZJQ1K4j/wGAHSAWgFlBdwmUPfhTpVR7DxwMYDtPcFAFKg08nZVP8Tt0KQ9QIEAV3iAI9ABUIEABAL9DDFQWmmwNn2WDIzFb29z5rl3FBPwVKshOsYSuMB8QeDAAXcLFjPkGtPz48XCNv39/RkuZUMoJJpmBmzkyeVzXeRXPdr2tgQIG8w5MQ0ygwm/gUEdKPX684IMDXgc1WHBAd7TlhN6tHKR7gdSYeB1E03z1ERBNWQ4w9ZohBWn30G7wwTMBBShx5p5R6LliEHvGpeSdZZchtoBO+G1UFoZ25eNUgILQBIGIOpHVQEqwOThIg4TM8yFEZc24j14ZBinkkEQWaeSRSCap5P+STDbp5JNQRinllFRWaeWVWGap5ZZcdunll2CGKeaYZJZp5ploogKRVFJ9gcCbcMYp55x01mnnnXjm6UKan6wplQEJ9FDAoIQWauihiCaq6KKMLroEF3yOMkACBQRg6aWYZqrpppx26umnni6hRaSiTFopqKimquqqmBJRA6mlUsrqrLTWGoAVRsAaiqm29uprpzogoCsovP5qrLFC7DmsJ8Ue6yytTASx7CfNPmttqkoUMS2zsl7rLagF/LBtJ9V+a26mPTgxLiflnutuEEmsu0m77n5rQxfyztttve5mEUW+mtDLr7VSTAFwJgIP7GwOox58ScIK/+rFqw4/vG//xNZa0UTFFp+KsbVXQMpxJRB/XOsSyo48SckmsxqtyiRf3LKvSuQK88oyz2xrsDfj7LHOvQqhbs+RsAw0qPASXXTOR69qg7ZKQ2J005yGG3UEDHgDTk1ZM7B1i0xTjWoPBhMdAWL8NAAO2rHlF7bYn+YAhNJAeQbPZg8AoNsEbAL6M9yoeoGv0mfHtgB0NL3T1J9vA75pFhsTPsF8sUWQeFxg/+24pwUIq/RkA+nmTWYpdZb55ql2HnVoh1EmgUohYXVP46hfqnrUDpTlnyAMiDSi25rXruntUT8y9ebEF9/I8Y4nr/wizAPu/POJRA/39NQfYr3Y2GdfyPZUdx8p/wNqsUu78OLziRG159eefprrcxu88Ji+L6afUi1go77zb5pCCkMIwBBSUIZr3UADqrJfmExTG/b1T1OC4EEAUgCAEVxLAwBIoOcihb+/OFBVg/hfBS2FBQ3wgAaWGgEVnmBBKoyABhq4wRCgoIEnWOqAGoCCDTGoQe9Br32WAsARfBADGozwBgC4AQ8AgEIA+EAQAcBgDGLgRClaKgYjuAERo5jB1G1QfRgJYzU+mCoAaIAKZhyhD44gQABIUIiX4iEFLcjDCR7wiVzsIalQwx3zPTBTZuTiCAMZgEASMo9zzKMRT3iEDNYRVQoUE30EwTcyoiqQFBzhEmkwAgBgof+QCLSUHEfIw06+kIp59OKwOCOIjlgSVISEwgiHsEQf3CCIoUQkKTM4hEZO0ZFdhOQXI8UPAyAGOvKjH+eGyacI6GY3X/OjMjsVyeeBr2nV9FI0Y/VH9DHzTASYAIBeOc36fdNMuVMJBdqSCfz5rZybyuaXnrGOomjCnUBE3jnTdBvf4YR/8BzePiNVgfeQK5/NG6gPr3k0eXrpKux4wDYxwVCgObRLxsTIh1ZEUYRKT6FkmiQAEkSNg3bTfSAdUzhrcpGumDSgmbool+bBjgFMIG/ShKntUiomy2GkMxBgJ8I8ej2eWpOo3DMqmOoTRmskU6eWkumW9rKO/QUMqeH/U+qXfMRNqEZVq156BjP+mVOoSlVLNK0qOQN61izFhk3lA6hX24qlMXZ1rmDt0uSaulZ40vVKEO2jXM2aV6JVVGd/5dhhZ5bYii22ZY112GNNFtk0YW09XJtKNCf7scpW6QDifAQEymKA/bBNNqfD67YwYxayJkIk/8Sb3sozu5OizrNWgkhcD4GZBYgkb5dbXFewis3CcqkCJBmAaxMBlAMgJmtxUVzfiNtQ42opJfB4ADIZgRnHjIQ0I2Vlagk7rAZMICgudYRIKoCYA7yOPmyprVcDgFsowcMAoLVqIl6klxj5rnycxVh9n2TMBejGdC9Vra5Guw4FTHSottXn/7QOwAChDlanA3aSRzZjoL6Ws3MtCMEF9liB0ipgu2XFMAJAIAABeIADfIKHedObYMJioMUtFsEJPnAmBYiEAiV9qlnJgOMiC6ADJigBmQ7gHa0gOMUwLQAYjExlEISAepNVQqO2zOVB9UAMVA4zBjzQAjAhxZ4enhUTcvCDPLn5zW8aQ5jnLAARzEDJW8LuOlB04V7pwGanaAGdB31kEbt1IM7Ub0cj7Ckb1GBuqJgBoScNAhhbibYjVXTHkGVdSrBg0qDGwI6ppBtjirfGtioA1FIB6lbnOMlRcqZenCrkWhEhBykLtKt3LQArj7hJyN2GctOcqh6ISxWS5vWux/9saSXtzjM4RfWslFCDeKmiA8rOto7xfCQQ0RjKq1rz0FJxgWybu8VI/jWRDueSExP7U39mBQfOTe9eNztIDBwnhGvlaEir4gT1rveYeRykZ6C51qsSQqctge2AB9zO3AbT9lTdinI7/OKFfkpgNW0J690616mYN8YxfuV0dAQjmWknm4bLaEsZ2xUeGPnIS/4UBXCUEvicnw0SpYNqOwIgnBCBzEc+g6e8hOMxm58UolCncTMC6JoowdBl7gFkBBbFfb6U3DAB9UyEYOpUP8bJPfLgRW/qaZnoOiZiDvaRg0DdV6KXDo59CbVfQuhtH3kH4O4LMfIV4ZZKVtqFgwn/qedd5nsPBh+RTol2uUoTdqfEBQB+eMRHfErt0hjkCU+JD3jgxpUfOgYI/ousrXy5Zs9UwTZviQuYAO+hB/vogRHYhkg7AFsfPCU4wOLYV372facQfBxgYGmjnfWQKMEJYO/70NN8F5juyrf3jam5byLyhrhACD7d/O4L4Pm5WABXcscbxi/tb4JHviI8D3rvex/8t6jAXhoAAQc8mfqWevz1OT8I1zPf/e5XdbtgDvp2VadCBDZwBZGjfoTAewD4gEYmgE0yKUvQA0EQBEYQBSBXd8KhfP8HgRAogUsyAGGAAC7gb50AEBzQcCDYgkXGAnx3JJgVCirogjZYZImn/yQzCApAR3k3aIM5OAtk0UDMcnOcAHXc94Mu2AGkFwu+ZRbmRS1GuH+EcAHth3E7sAFauAHnBgMWgAM4YAEw0H3ABxWbMVJYFzBTyIAA8AFDlwGEcG5wuAE7kAFcSIZNqCHONQAXEQkQ4F4b0TWbtYa6VwgmMHQbAAAW0GIwkAEvQAIkgAMCgAQyYAEWkAEC0IiMiIlzWIdc2IiPGIktVgUWQAIv0GIb4IiQiAQZIIYtVokWsAWSSGgYcG+tcGL4QGuNwGAKcVr5QYhcx39sh3GJuIgCYAEAgAIrkIwCgAIqkAEygALHCAAthowCMIeJiInIqIzMKAMAIAMkAACnCP+HKrCM5agCALADzQiNKiCNoAZ/rUAB98cI5DEQsqUbGLKDn2B3F8CCDleM1UiNArCMAqACKrAFGaCO1jiN1wgAWggA2iiQBFmOkwgAJNCQXKiIGCkAG1CJ6Ohq8JgKf7gMqIcIAzAj0ZWSwtUUoxB5H3CF9QaQDMmQOEACKAAAKrADC2mN2AiRM2mNGikAGjmHQrmIc/gCFvkCBOlqJuAKz6RWu1gelzMQ0vUnwMiBiSByAbcDVQAAK8CFO0mNYrgByFiTFikDH9mTERmQAhCOLwCHVbCRQ+mQcOiIN8lrIpgKb+VBy2MQo2MNpXMPV2kJ2AcAPkhvcDgIP0mN4Zj/jGOIAzdJAgSplos5ieGoAjLQYkQ5lxuABMuIAneJl6xgV5BwEvMwAVkBO/HVIoNZCYUJAEmohDaYl6bAZH9nPJjTOyoBYK1JCa9phbL5g0FoClQlWGrYkvxXCG4YnDc4nKTAVbvSm5PwmoJwiMwJhDEYCh0xVlKInI4wjNcJgmU4ChvXnaJAnYLQj+HpguMZCqbHl+QinZKAnoLwkuvZgu0pCkFFLPIZCfQpCCEAk/fpfRgQkpuwYetQkg/Tn5Dwn+nZewPqfgXakiW2AO5WhN4pCRwgoBF6eCeQnSnIZHxjfpKgj57goFUIoR2ad0xoCj7GGUEWnxm6exy6og6H/wFNeQpMpgBOZp40mJyPcAEqaqMO93bAYaIpCKSQsKFE+nBlpgoWcZvswqCPgKKJIKRNem5FxwrkAZUyep5KqqE1mqVzxgKXp5ehAQCVhKFg2glYSqa0aKCnAA/04Ups+qOfwKRwGmYf6oQ2VU8+yoNhWglvuqfo9qSxAAEQ4EwSFaj7OKiWoKdkiqM6SKU/B6mtN6QrCgJnqiGoQaJFY6mNYKWTIKkRKgKIOgt+lxSOeqKYigmFep8zAKJGgqRH+KqZYKrByQJ5WAslZlDROaOmEKs/OKG6wFrrYGGW4E6i+nS4ugkcEJsu6AG0OgsnWQHy16yEwKzCSm4m4I8A2P8BqaoL6cWS/Nmtq1AC3yqhW+oLDOSlU4quraCu4Jp3nBoM72qcCKOtikCqo+CBeScCtlgltkqFuPAByzd0faolBcuGt4CwH5htvNolDVuIvdACn2dulOolFRuMwsABGetq1Cpx/JoI/hoLIDumOTauFFuyiHCysxACmioAGNCuC+Sy//CsuaB9EGqmZdKxWPkUrjewNyuvPmQKQEuYOnu0x9mmTKsKSeuaS/u0C2q0VBusTnu1SIuzhgCzWhuqVvu1X4qnYksKUeubU6sNi6C2sxETbKsNcBsP2fAQBYgIbLutbpu3P+EbdTsMZzudUwu0trqDhKsQmHW4bBIQvTn/uE5RuKypuE/xt/MZuFfJuL94uZCbuSuXuY5guYKJueshueTKtYXgr4JrhI77uZpruIl7tp77uKobuqTbCdygNYGoWZhLtiVauajbuL4Lu4gru1LTu7m7upybCxAlG76ouroLtu5AvMxrvKsrvMYDvbALvFQ5u5zQEi9xN7sxW3zzJ8K1cuRbvuZ7vuibvuSLEeorvufLvn0zvvA7v4sjRl0xvu0Lv+Wrv/e7cvTbv/+xC2wRXO1bwAZ8wAicwAq8wAzcwGzSt7AAXlNZtr/wHIIAXoFJwbzQH//xXrGjrBrMECoCALr5OyF8wiicwipsJgegoJhwDo7QwoNwWV5z/7skMQjItU6cIMO3W8Ms4Q0gbAmX9Q09/DU5HMS30BP6unnswF2KMwjLaxoNQA4pARZTnAlK7CDLW8VbgcSSUDhpszZm0TbhZcVeTAtXAaqT6xCLkMYs8b34+BDkIDoRACTghQlurBlwXB513ABHkXL31DYZcY98bMeA3As4IqhEAcF9oR0TPAjzwAA4ksgv7BpTOclLTAmF42OIk5K9cReUjMiZjAm8oSNnnMiPDACY4Q+YrMaKgMqe3MqcMA2U42CXDMqjbAuhDArx8cqugcHiRRYOpsptI1vt9MukwxmrrMfRlgmgM1t/GV4UsMzG3AsQMBlBUXbLanM6os0Vgf/N4uHB8TUZMzIVALBeurFbk3DNsRHOqik76Nwcm8A6zuU670wO8azOuBBYjCwJEkAeCuDCP8IO6FDCJNIYqowY0HkJ/EzC/1URCq2LmpBOz2bQED1rK5zRGr3RHN3RHv3RIB3SIj3SJF3SJr0Kc+sIpCkJz3AfEk2euvgM4DAODpMP9Lc8+tyX6GDOc2oj+tMimAMw7TAZwMUAPVETHfERLWIPWVNQD4ATSFEN2HDDEHEbxMHUEfEAT223vaHV0XAbEgENJeZUNqHUC9IXOkETB9MOOKIX7TAXdXEX/GCholEYdAERxAEPxiHXKiEiJmkWJ+nHtJE2T2gPcH3F3DHoOfcQ1PkSFc9lF7KhGnrcGoqxHIgxW7yx03mN1+jA14Jw2dpjGZGhHPqQEJLNGmddx7Sm1kJtFgagE65hHQPh2XZTE+e1Z8ZRHKdR2QdRIvmx2aT9IJ88EL/hGqHxT6zd2ITHHQRiHwuyHJ8xIRUij28FE3vN2z9CzI3LGfIn2HHxGb/R3B3mGgqAWsOxOP2cJl3HHfxlwrT9GSeJ0RHADwqgG5z93L2tD5PBTvqhEiDx3aUdF+0N24qBGQA2wifNH1hnHJgwOd6c4PwhVAx+CRSQ0xB+4Rie4Rq+4Rze4R7+4SAe4mESCAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between plasma glucose and proinsulin concentrations in normal subjects and patients with an insulinoma after a prolonged fast. In patients who become hypoglycemic, a plasma proinsulin concentration above 5 pmol/L is suggestive of an insulinoma. To convert plasma glucose values to mmol/L multiply by 0.056.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Service, FJ, N Engl J Med 1995; 332:1144.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32541=[""].join("\n");
var outline_f31_49_32541=null;
var title_f31_49_32542="Gingivitis mouth breather";
var content_f31_49_32542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gingivitis associated with mouth breathing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 152px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ann Griffen, DDS, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32542=[""].join("\n");
var outline_f31_49_32542=null;
var title_f31_49_32543="Diagnostic approach to isolated neutropenia";
var content_f31_49_32543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Diagnostic approach to isolated neutropenia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 383px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; PE: physical examination; ESR: erythrocyte sedimentation rate; FTT: failure to thrive.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_49_32543=[""].join("\n");
var outline_f31_49_32543=null;
